

RESUME

Professor Allan David SPIGELMAN

Contents:

Part 1: Education History

Part 2: Career History

Part 3: Research Degree Supervision

Grants

Journals Refereed

Publications

Presentations

Part 4: Committees

PART 1: EDUCATION HISTORY

Secondary education: Sydney Boys High School 1965-1970
(Vice Captain 1970)

Tertiary education: Sydney University 1971-1976
Clinical: Royal Prince Alfred Hospital (1973-1976)

TERTIARY DEGREES / QUALIFICATIONS:

MB BS 1977 (The University of Sydney)
FRACS 1985
FRCS (ad eundum) 1995
MD 1996 (The University of Sydney)
Title: Studies of the Foregut in Patients with Familial Adenomatous Polyposis: the Clinical Problem, Management and Pathogenesis.

REGISTRATION:

UK General Medical Council
(No. 3035322; T{S})

NSW Medical Board
(No. MPO 0108207)

Medical Board of Australia
(from 1 July, 2010; No: MED0000981634)

PART 2: CAREER HISTORY

Present: Professor of Surgery, University of NSW, St.Vincent's Hospital Clinical School

Other Current: Member N.S.W Medical Board of the Medical Board of Australia (2016-2018)
Honorary Senior Research Fellow, The Polyposis Registry, St. Mark's Hospital, London
Member, South Eastern Sydney Local Health District (SESLHD) Board (2017 -)
Member, SESLHD Board Healthcare Quality Committee (2017 -)

Recent Past: Member, Collaborating Hospitals Audit of Surgical Mortality (CHASM 2008 - 2019)
Clinical Associate Dean, St.Vincent's Hospital Clinical School, University of NSW (2007 - 2016)
Director of Cancer Services, St.Vincent's & Mater Health Sydney, then SVHA (2006-2015)
Director, Cancer & Immunology Program, St. Vincent's Hospital, Sydney (2006-2015)
Honorary Senior Medical Officer, Hunter New England Area Health Service
Visiting Medical Officer, Cancer Genetics, Sydney Western Area Health Service – Royal Prince Alfred and Liverpool Hospitals (2008-2011)
Honorary Medical Officer Central Coast, Mid North Coast and Northern NSW Local Health Districts
Member, Governing Council, International Society for Gastrointestinal Hereditary Tumours (2005 -); Chair Elect (2009-2011); Chair (2011-2013)
Conjoint Professor of Surgical Science, Faculty of Health, University of Newcastle (2004 -)
Member, N.S.W Medical Board (representing Universities of N.S.W; 2003 - 2010)
Member, N.S.W Medical Board of the Medical Board of Australia (representing Universities of N.S.W; 2010 - 2012)
Expert Advisor, N.S.W Medical Board of the Medical Board of Australia (2015)
Member, N.S.W Medical Council (2010 - 2012)
Member, NSW Registration Committee, Australian Health Professionals Regulatory Authority (2012 -)
Member, NSW Medical Board (2016 -)
Founder and Director, Hunter Family Cancer Service (1997 -)
Director St Vincent's Hereditary Cancer Clinic; then St Vincent's Cancer Genetic Service, (2007 -)
Chair, Advisory Committee, NSW & ACT Hereditary Cancer Registers (1997 - 2010)
Acting Director, The Kinghorn Cancer Centre, Sydney (2012 - 2014)
Clinical Director, The Kinghorn Cancer Centre, Sydney (2012 - 2015)
Director, Hunter New England Clinical Governance Unit (2005 -2006) preceded by
Director of Clinical Governance, Hunter Area Health Service (1999-2004)
Area Director of Cancer Services, Hunter New England Area Health Service (2005-2006) preceded by Area Director of Cancer Services, Hunter Area Health Service (2003-4)
Chair, Division of Surgery, John Hunter Hospital (1998 - 1999)
Director, John Hunter Hospital Surgical Audit Unit (1997 – 2001)
Professor of Surgical Science, Faculty of Health, University of Newcastle (1997 – 2003)

1990-1997: Senior Lecturer and Honorary Consultant Surgeon, Academic Surgical Unit, St. Mary's Hospital, London and the Central Middlesex Hospital, London
Director, St. Mary's Hospital Breast Group
Director of the St. Mary's Hospital Day Care Unit
Lead Clinician, St. Mary's Hospital Carelink Information Systems Project
Lead Clinician, St. Mary's Hospital Family Cancer Service

- Assistant Director, Medical Education Unit, St. Mary's Hospital Medical School
Member, Academic Board of the St. Mark's Academic Institute
- 1988-1989:** Surgical Research Fellow, St. Mark's Hospital & Professorial Surgical Unit, St. Bartholomew's Hospital
Honorary Clinical Assistant, St. Mark's Hospital
- 1985-1987:** Senior Surgical Registrar, Kings College Rotation, London
Surgical Registrar University College Hospital, London
Senior Surgical Registrar, University College Hospital and the Middlesex Hospital, London
Honorary Clinical Assistant - St. Mark's Hospital, London
- 1985:** Private Practice, Sydney; Visiting Surgeon, 4 RAAF Hospital Air Base Butterworth, Malaysia
- 1981-1984:** Surgical Registrar, Advanced Training Scheme, Royal Australasian College of Surgeons - Prince of Wales Hospital, Sydney
- 1977-1980:** Resident Medical Officer, Royal Prince Alfred Hospital, Sydney
Junior Registrar, Surgery, Prince of Wales Hospital, Sydney
Senior Resident Medical Officer, Surgery, Prince of Wales Hospital, Sydney

AWARDS

- McNeill Love Prize for Excellence in Surgery, The Royal Northern Hospital, London 1987
- Alan Edwards Memorial Prize, The Royal Society of Medicine, for Best Presentation to the Clinical Section 1988-1989
- Hewlett Packard Innovation and Quality in Health Care 'Golden Helix' Award, United Kingdom, awarded for establishing the St. Mary's Hospital, London, *One-Stop Breast Service* 1995
- Australian Cancer Network, Australian Cancer Society & the Clinical Oncological Society of Australia – Certificate of Exemplary Service; for commitment to *Development of Best Practice Guidelines 2000*
- NSW Department of Health Baxter Better Health Care Awards (2000) Excellence in Health Care Category, "*The Prevention of Infection in Prosthetic Joint Replacement*"
- Certificate of Appreciation for significant contribution to the development of the Princess Alexandra Hospital Health Service District, Brisbane, *Patient Safety System*, 2002
- Commonwealth Bank Quality Award, "Quit Smoking for Surgery" project 2003 (\$500)
- Best free paper presented by a Fellow at the Royal Australasian College of Surgeons Annual Scientific Congress, Brisbane, May 5-9 2003 (\$500): Title: *'What happens to patients after discharge?'*
- Peter Reizenstein Prize for best paper published in the International Journal for Quality in Health Care in 2002 (£500) for: *Adverse Events in Surgical Patients in Australia*
- Hunter Medical Research Institute / New South Wales Cancer Council Prize (2003) for *Outstanding Achievements in Cancer Research*
- Baxter NSW Health Award (2003) Information Management Category, "*Aiming for a Safer Patient Environment*"
- Featured Researcher – Colorectal Surgical Society of Australasia 2005
- Highly Commended Award Winner, Literati Network Awards for Excellence 2012, for paper entitled: *Clinical governance: a review of key concepts in the literature*
- UNSW St Vincent's Clinical School Publication Prize 2012
- UNSW St Vincent's Clinical School Community Service Prize 2014

MEMBERSHIP OF LEARNED SOCIETIES & PROFESSIONAL ORGANISATIONS

The Royal Australasian College of Surgeons

The Royal College of Surgeons of England

The Surgical Research Society of Great Britain and Ireland (1989 to 2001); name change to Society of Academic and Research Surgery (2001); resigned in 2004

The Royal Society of Medicine - Member of Council, Clinical Section; 1991-1994; Vice-President, Clinical Section; 1994; Library Representative 1995-1997

The British Society of Gastroenterology (to 2002)

The British Medical Association (1988 - 2002)

The St. Mark's Association

The Leeds Castle Polyposis Group (1988 – 2004); Member of Council 1999 - 2003; Chairman, LCPG Upper Gastrointestinal Disease Committee

International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (to 2004)

The International Society for Gastrointestinal Hereditary Tumours (InSIGHT - created by merger of the above 2 Groups; 2004 - ; elected Member of Governing Council 2005 – 2009; elected Deputy Chairman and Council Member 2009-2011; Chair 2011-2013, council Member 2013 -)

International Society of University Colon and Rectal Surgeons (to 2005)

The Association of Coloproctology of Great Britain and Ireland (to 2003)

The European Cancer Prevention Organisation (1990 – 1997)

British Association of Day Surgery (1994 - 1998)

North West Thames General Surgeons Club (1995 - 1997)

British Medical Informatics Society (1994 - 1998)

Medical and Dental Education Network (United Kingdom 1993 - 1997)

Surgical Research Society of Australia (Life Membership)

Colorectal Surgical Society of Australasia (to 2005)

Australian Resource Centre for Hospital Innovations (Member, Local Management Committee 1998-2000)

Hunter Postgraduate Medical Institute (Board Member, 2001 - 2006)

Australian Gastro-Intestinal Trials Group (2001 -)

Section of Academic Surgery, Royal Australasian College of Surgeons (2002 -)

Member, N.S.W Medical Board (representing Universities of N.S.W; 2003 – 2007; 2007 - July 1, 2010)

Member, NSW Medical Council of the Medical Board of Australia (July 1, 2010 - 2012)

Member, NSW Registration Committee, Medical Board of Australia, Australian Health Practitioner Regulation Agency (2012 -)

Member, Queensland Registration Committee, Medical Board of Australia, Australian Health Practitioner Regulation Agency (22 May 2013 - 30 September 2013)

The Cancer Council NSW (2006)

Australian Medical Association (2010 - 2013)

International Cancer Benchmarking Partnership (2010 -)

Academy of Surgical Educators, Royal Australasian College of Surgeons (2011 -)

Human Variome Project Consortium (2011 -)

European Hereditary Cancer Group (2019 -)

PART 3:

- RESEARCH DEGREE SUPERVISION
- UNSW MEDICAL STUDENT INDEPENDENT LEARNING PROJECT THESIS SUPERVISION
- GRANTS
- JOURNALS REFEREED
- EDITORIAL BOARDS
- PUBLICATIONS
- PRESENTATIONS

RESEARCH DEGREE SUPERVISION

- *New South Wales Colorectal Cancer Patterns of Care Survey*. Co-supervisor of PhD candidate, Dr. David Leong (1998 - 2002) - University of Sydney, NSW Australia
- *Prognostic factors in Abdominal Aortic Aneurysm Surgery*. Supervisor of BMedSci candidate, Mr. Stuart McKenzie (1999) – awarded - University of Newcastle, NSW, Australia
- *Surgeons' Practices and Attitudes Regarding Euthanasia*. Co-supervisor of MS candidate, Dr. Charles Douglas, funded by a competitive grant from the Royal Australasian College of Surgeons Foundation Scholarship in Surgical Ethics (1999) - University of Newcastle, NSW, Australia
- *Measurement and Prevention of Adverse Events in High Volume Elective Surgical Procedural Groups in an Acute Hospital Setting*. Co-supervisor of PhD for Ms. Ashley Kable (1998-2004) – awarded 2004 - University of Newcastle, NSW, Australia
- *Aviation and Surgery: Behaviour in the Operating Room*. Co-supervisor of PhD candidate Ms Rebecca Atkins (2002-2005) - University of Newcastle, NSW, Australia
- *Selected Studies of the Aetiology, Prevention and Management of Colorectal Cancer*. Supervisor of PhD candidate Dr Daniel McGrath (2001-2006) – awarded 2007 - University of Newcastle, NSW, Australia
- *Spinal Fusion Research*. Co-supervisor of MS for Dr Michael Ow-Yang (2008-2009) – University of New South Wales
- *A Study of the Haemodynamics of Vein Grafts using Computational Fluid Dynamics Techniques*. Co-supervisor of MD for Dr Mark Jackson (2007-2008) – awarded 2008
- *Psychosocial implications of facial injuries: a phenomenological inquiry of patient's experiences*. Co-supervisor of MS for Dr Lara Wetton (2011-2012)
- *Strategies for the Management of Malnutrition and Associated Complications in Head and Neck Cancer*. Co-supervisor of Masters of Health Science for Amanda Duffy, University of Sydney (2015 – 2017)

UNSW MEDICAL STUDENT INDEPENDENT LEARNING PROJECT THESIS SUPERVISION

- Analysis of patient reports on the referral process to two NSW cancer genetic services. Student: Butel-Simoes GI. 2012
- Attitudes and knowledge of medical practitioners to hereditary cancer clinics and cancer genetic testing. Student: Teng I .2013.
- Adherence to guidelines for the referral of patients with colorectal cancer and abnormal immunohistochemistry tumour tissue testing for assessment for Lynch Syndrome. Student: Julian Han. 2017
- Adherence to guidelines for the referral of patients with triple negative breast cancer (TNBC) for breast cancer gene testing. Student: Michel Lu. 2017.
- Adherence to guidelines in Lynch syndrome patients. Student: Li Han Goh 2019.

• **GRANTS**

Title	Funding Body	Year	Amount
Same Day Breast Lump Assessment Service	Kensington, Chelsea & Westminster Health Authority, London	1994 1995	£54,000 £27,000
Clinical Audit projects	Kensington, Chelsea & Westminster Health Authority, London	1994	£29,000
Information Technology Project	Friends of St. Mary's Hospital, London	1994	£3,000
Establishment of Regional Family Cancer Registry	N.S.W Health	1997	\$121,000
Surgical Audit Facilitator	Hunter Area Health Service	1997/98 1998/99 then recurrent	\$50,000 \$80,000 \$80,000/year
Rural Senior Lecturer in Surgery	Hunter Area Health Service	1997/98 1998/99 then recurrent	\$80,000 \$100,000 \$100,000/year
Establishment of a Clearing House to evaluate and disseminate results of the National Hospital Demonstration Project	Commonwealth Government of Australia	1998/99	\$168,000
Cancer risk	Newcastle Permanent Building Society / HMRI	1998/2004	\$300,000
Variations in clinical management & histopathology reporting for colorectal cancer in N.S.W	Medical Benefits Fund of Australia	1998	\$35,000
Inter-practitioner variability in the management of colorectal cancer and its impact on tumour relapses in N.S.W	National Health & Medical Research Council (Australia)	1999	\$244,507.43
Elective Surgery Resulting in Adverse Events in Australian Hospitals	New South Wales Ministerial Advisory Committee on Quality in Health Care	1998/1999	\$40,000
National Colorectal Cancer Patterns of Care Survey	Commonwealth Department of Health & Aged Care; National Cancer Control Initiative	1999 - 2000	\$211,300
Surgeons' Practices and Attitudes Regarding Euthanasia	Royal Australasian College of Surgeons Foundation Scholarship in Surgical Ethics	1999	\$28,600
Hunter Family Cancer Service	Elaine Heyworth Bequest	1999	\$10,000

Evidence-based indicators for quality care in General Practice - Newcastle Institute of Public Health	Commonwealth Department of Health & Aged Care	1999	\$100,000
Clinical Support Systems Project – Toward a Safer Culture	Royal Australian College of Physicians	2000/2001	\$1,000,000
Newcastle Bowel Cancer Collaborative	Hunter Medical Research Institute	2000	\$37,000
Randomised Controlled Trial of a Computerised Smoking Cessation Intervention in a Surgical Pre-admission Clinic	National Heart Foundation of Australia	2000/2001	\$70,000
	The Cancer Council NSW	2001 - 2003	\$93,000
Appropriateness Criteria for Cholecystectomy & Cataract Procedures	NSW Health Quality & Clinical Policy Branch	2002-2003	\$30,000
Breast Cancer Biospecimen Resource	NHMRC	2004-2009	\$2,000,000
	National Breast Cancer Foundation	2005-2009	\$380,000
	Cancer Institute NSW	2005-2006	\$326,598
	National Breast Cancer Foundation Facilitation Grant	2007-2011	\$1,454,090
	Cancer Institute Research Infrastructure Grant	2009-2011	\$450,000
	NHMRC Enabling Grant	2011	\$400,000
		2012	\$400,000
		2013	\$400,000
		2014	\$200,000
		2015	\$200,000
Measurement for Improvement Toolkit	Australian Government: Dept. of Health & Aging	2005-2006	\$354,000
The Colorectal Cancer Research Consortium: a model for the integration of biomedical research into patient care	The Cancer Council, NSW	2006- 2010	\$1,312,104
Clinical Cancer Research Support	Cancer Institute NSW	2006-2007	\$280,000
Lung Cancer Multidisciplinary Clinic	Cancer Institute NSW	2007-2008	\$160,000

Referral Pathways in Colorectal Cancer: General Practitioners' Patterns of Referral and Factors that Influence Referral.	Cancer Australia & NHMRC - 2007 Priority Driven Collaborative Research Scheme	2008-2010	\$598,750
Garvan St Vincent's Campus Cancer Centre (The Kinghorn Cancer Centre)	Australian Cancer Research Fund 2008	2008	\$2.5 million
	Commonwealth Government of Australia	2009	\$70 million
St Vincent's Hospital	Molecular imaging using fluorescent laser scanning confocal endomicroscopy for cancer surveillance in Barrett's oesophagus and ulcerative colitis	2010	\$148,260
Kinghorn Cancer Centre Screening for Pancreatic Cancer in High Risk Australians (Chief Investigator - Clinical)	Cancer Institute NSW	2010	\$599,771
i) Provision of a clinical training and education facility to support medical students undertaking clinical placements in the Pre Admissions Centre at St Vincent's Private Hospital, Darlinghurst:	Health Workforce Australia Grants	2011	\$102,055
ii) Upgrade of the audiovisual equipment in the DMLT Lecture Theatre, St Vincent's Public Hospital		2011	\$94,154
iii) Integrated Clinical Masterclass		2012	\$77,500
iv) Clinical Teaching Area Refurbishment		2014	\$20,000
v) Video Conferencing Equipment		2014	\$12,000
vi) Skills Laboratory Refurbishment		2015	\$13,700
The effects of butyrylated high amylose maize starch on polyposis in familial adenomatous polyposis patients	Cancer Council Australia & Cancer Councils, NSW, Queensland, Victoria and South Australia, working with the CSIRO	2011-2013	\$950,353
Oncology Information System	Curran Foundation	2012	\$350,000
Hermina Rich Bequest for Cancer Research	Curran Foundation	2012	\$950,000
Shine Translational Research Grant funding	Garvan & St Vincent's Board Chairs	2012	\$500,000

Third National Prostate Cancer Research Centre	Commonwealth of Australia	2013	\$6 million
Heather Rivers Grant to support Cancer Genetics	Curran Foundation	2014	\$550,000
Identification of men with a genetic predisposition to Prostate Cancer: Targeted screening in BRCA1/2 mutation carriers and controls – The IMPACT study (AI)	Cancer Australia	2010 – 2013	\$473,027
	Cancer Australia PCFA APP#1059423	2014 -2 016	\$584,302
A worldwide study of cancer risk for Lynch syndrome	NHMRC (AI)	2014-2017	\$690,000
Provision of Specialist Advice and Technical Expertise to support Phase One of the Best Practice Indigenous Cancer Care Project (with Synergy Health and Business Collaborative)	Cancer Australia	2016	\$52,250
Extending the strategic importance of the Australian Breast Cancer Tissue Bank to facilitate breast cancer research	National Breast Cancer Foundation	2016 -2017	\$375,000
Concerted Action Against Polyposis Study (CAPP3)	UNSW St Vincents Clinical School	2018	\$10,000
	CAPP3 University of Newcastle-Upon-Tyne, U.K,	2018	\$100,000
Cancer Genetics Unit support	William Kopsen Foundation	2018	\$200,000

JOURNAL REVIEWER

I am or have been a reviewer for the following journals:

1. The British Journal of Surgery
2. The European Journal of Cancer Prevention
3. Surgical Oncology
4. International Journal of Colorectal Disease
5. European Journal of Gastroenterology and Hepatology
6. Cancer Detection and Prevention
7. Quality in Health Care
8. American Journal of Gastroenterology
9. Medical Journal of Australia
10. British Medical Journal
11. Gut
12. Australian & New Zealand Journal of Surgery
13. Journal of the American College of Physicians
14. Colorectal Disease
15. Journal of Quality in Clinical Practice
16. Clinical Evidence
17. Thrombosis Research
18. Scandinavian Journal of Gastroenterology
19. International Journal for Quality in Health Care
20. Digestive and Liver Disease
21. Diseases of the Colon & Rectum
22. Medicine Today
23. Therapeutics and Clinical Risk Management
24. BMJ Evidence Centre – Specialist Review Panel (2009)
25. Cancer Epidemiology, Biomarkers and Prevention
26. Hereditary Cancer in Clinical Practice
27. BMC Surgery
28. Journal of Medical Genetics
29. Current Medicinal Chemistry
30. Australian Medical Student Journal (AMSJ)
31. PLOS ONE
32. Australian Health Review
33. Genome Medicine
34. Asia-Pacific Journal of Surgical Oncology

EDITORIAL BOARDS

1. Therapeutics and Clinical Risk Management
2. Hereditary Cancer in Clinical Practice – published under the auspices of the *UICC*
3. Clinical Governance: An International Journal (Regional Editor – Australia & New Zealand) to 2016
4. International Journal of Health Governance (Regional Editor – Australia & New Zealand) from 2016
5. International Medical Case Reports Journal

PUBLICATIONS:**BOOKS**

1. *Familial Adenomatous Polyposis and Other Polyposis Syndromes*. (eds) Phillips RKS, Spigelman AD, Thomson JPS. ISBN 0-340-56755-4. London: Edward Arnold 1994.
2. The National Colorectal Cancer Care Survey - Australian Clinical Practice in 2000. Spigelman AD, McGrath DR. ISBN 1 876992 00 X www.ncci.org.au Commissioned by the National Cancer Control Initiative on behalf of the Commonwealth Department of Health and Aged Care, 2002.
3. The New South Wales Colorectal Cancer Care Survey 2000. Part 1. Surgical Management. Armstrong K, O'Connell D, Leong D, Spigelman A, Armstrong B. ISBN 1 86507 073 4 www.cancercouncil.com.au The Cancer Council NSW April 2004.
4. The New South Wales Colorectal Cancer Care Survey 2000 Part 2 - Chemotherapy Management. Armstrong K, O'Connell DL, Leong D, Yu XQ, Spigelman AD, Armstrong BK. ISBN 1 86507 078 8. www.cancercouncil.com.au The Cancer Council NSW July 2005.
5. The New South Wales Colorectal Cancer Care Survey 2000 Part 3. Radiotherapy Management. Armstrong K, Kneebone A, O'Connell D, Leong D, Yu XQ, Spigelman AD, Armstrong BK. ISBN 1 92104 128 5 www.cancercouncil.com.au/editorial.asp?pageid=2376 The Cancer Council NSW November 2007.
6. The New South Wales Colorectal Cancer Care Survey 2000 Part 4. Follow-up practices and outcomes after curative surgery. Armstrong K, O'Connell D, Leong D, Spigelman AD, Armstrong BK. www.cancercouncil.com.au The Cancer Council NSW.
7. Collaborating Hospitals' Audit of Surgical Mortality – Case Booklet January 2008 – June 2009. Clinical Excellence Commission (CEC) 2010. ISBN 9-780-9805-543-28. Sydney: CEC.
8. Collaborating Hospitals' Audit of Surgical Mortality – Case Booklet July 2009 – June 2010. Clinical Excellence Commission (CEC) 2010. ISBN 9780-9805543-5-9. Sydney: CEC.
9. Collaborating Hospitals' Audit of Surgical Mortality – Casebook 2011. Clinical Excellence Commission (CEC) 2011. ISBN 978-0-9805543-5-9. Sydney: CEC.
10. Clinical Excellence Commission (CEC) 2012. Collaborating Hospitals' Audit of Surgical Mortality (CHASM) Casebook 2012. Sydney: CEC.
11. Clinical Excellence Commission (CEC) 2013. Collaborating Hospitals' Audit of Surgical Mortality (CHASM) Casebook 2013. Sydney: CEC.
12. Clinical Excellence Commission (CEC) 2014. Collaborating Hospitals' Audit of Surgical Mortality (CHASM) Casebook 2014. Sydney: CEC.
13. Clinical Excellence Commission (CEC) 2015. Collaborating Hospitals' Audit of Surgical Mortality (CHASM) Casebook 2015. Sydney: CEC.

CHAPTERS

1. Management of Familial Adenomatous Polyposis. Spigelman AD Hodgson SV, Thomson JPS in (ed.) Henry MM. *Bailliere's Clinical Gastroenterology: Anorectal Disorders*. London: Bailliere Tindall 1992; 6 (1): 75-94.
2. ³²P-Postlabelling studies of target tissues and bile from patients with familial adenomatous polyposis and from unaffected controls. Scates DK, Spigelman AD, Phillips RKS, Venitt S in (eds.) Phillips DH, Castegnaro M, Bartsch H. *Postlabelling Methods for Detection of DNA Adducts*. Lyon, International Agency for Research on Cancer 1993; 357-364.
3. Nomenclature: Familial Adenomatous Polyposis (Bussey-Gardner Polyposis). Spigelman AD, Thomson JPS, Phillips RKS in (eds.) Phillips RKS, Spigelman AD, Thomson JPS. *Familial Adenomatous Polyposis and Other Polyposis Syndromes*. London: Edward Arnold 1994; xiii-xiv.
4. The Upper Gastrointestinal Tract. Spigelman AD, Phillips RKS in (eds.) Phillips RKS, Spigelman AD, Thomson JPS. *Familial Adenomatous Polyposis and Other Polyposis Syndromes*. London: Edward Arnold 1994; 106-127.
5. Peutz Jeghers Syndrome. Spigelman AD, Phillips RKS in (eds.) Phillips RKS, Spigelman AD, Thomson JPS. *Familial Adenomatous Polyposis and Other Polyposis Syndromes*. London: Edward Arnold 1994; 188-202.
6. Introduction, History and Registries. Spigelman AD, Thomson JPS in (eds.) Phillips RKS, Spigelman AD Thomson JPS. *Familial Adenomatous Polyposis and Other Polyposis Syndromes*. London: Edward Arnold 1994; 3-14.
7. Genetics. Hodgson SV, Spigelman AD in (eds.) Phillips RKS, Spigelman AD, Thomson JPS. *Familial*

- Adenomatous Polyposis and Other Polyposis Syndromes*. London: Edward Arnold 1994; 26-35.
8. Open Repair of Groin Hernias. Spigelman AD in (eds.) Darzi A, Monson JRT. *Laparoscopic Inguinal Hernia Repair*. Oxford: Isis Medical Media Ltd. 1994; 6-17.
 9. Cholecystectomy and Colon Cancer. Spigelman AD, in (eds.) Darzi A, Grace PA, Pitt HA. Bouchier-Hayes D. *Techniques in the Management of Gallstone Disease*. London: Blackwell Science 1995; 218-223.
 10. Open hernia repair. Spigelman AD. MATTU Handbook. RCSE 1995.
 11. Epidemiology and Pathogenesis of Large Bowel Cancer. Spigelman AD in (ed.) Allen-Merish T. *Surgical Oncology (Companion to Bailey and Love's Short Practice of Surgery)*. London: Chapman and Hall 1996; 205-216.
 12. The Small Bowel, Colon, Rectum and Anus. Spigelman AD, Phillips RKS in (eds.) Fielding JWL, Allum WH. *Premalignancy and Early Cancer in General Surgery*. Oxford: Oxford University Press 1996; 37-65.
 13. Screening and Surveillance in Familial Adenomatous Polyposis. Spigelman AD, Williams CB in (eds.) Beger HG, Warshaw AL, Buchler M, Carr-Locke D, Neoptolemos JP, Russell C, Sarr M. *The Pancreas*. Blackwell Scientific Publications 1997; 1311-1315.
 14. Inherited Bowel Cancer. Spigelman AD, in (ed.) Phillips RKS. *A Companion to Specialist Surgical Practice: Colorectal Surgery*, Volume IV, Colorectal and Small Bowel Surgery. London: W.B. Saunders 1998; 33-42.
 15. Inherited Bowel Cancer. Spigelman AD, in (ed.) Phillips RKS. *A Companion to Surgical Practice: Colorectal Surgery*, 2nd edition: Harcourt Brace & Company Ltd 2001; 35-52.
 16. Acute Abdominal Conditions – Surgical Aspects. Spencer J & Spigelman AD, in (eds.) Henry MM, Thompson JN. *Clinical Surgery*. London: W.B. Saunders 2001; 315-326.
 17. Clinical Governance – An approach to delivering safer care. Spigelman A, in (eds.) Emslie S, Williams S, Barraclough B. *Enhancing the Safety of Care*, Australian Safety & Quality Council www.safetyandquality.org & Northern Territory Department of Health and Community Services, ISBN 0 7245 3372 9, 2002.
 18. Acute Abdominal Conditions. Spigelman AD, in (eds.) Henry MM, Thompson JN. *Clinical Surgery*. London, 2nd Edition: W.B. Saunders 2005; 365-376.
 20. Acute Abdominal Conditions. Spigelman AD, in (eds.) Henry MM, Thompson JN. *Clinical Surgery*. London, 3rd Edition: W.B. Saunders 2012; 341-351.
 21. Small Bowel Tumours: Molecular Mechanisms and Targeted Therapy. Spigelman AD and Warusavitarne J, in (eds.) Gelmann E, Sawyers C and Rauscher F III. *Molecular Oncology: Causes of Cancer and Targets for Treatment*. Cambridge University Press. 2014; 542-546. ISBN 078-0-52187662-9.

PAPERS (Peer reviewed)

1. Isolated Congenital Pulmonary Incompetence: Case Report and Literature Review. Spigelman AD, Wright JS. *ANZ J Surg* 1984; 54; 177-181.
2. Cholecystectomy, duodeno-gastric reflux and polyposis. Spigelman AD, Thomson JPS, Phillips RKS. *J Roy Soc Med* 1989; 82: 436-7.
3. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Spigelman AD, Williams CB, Talbot IC, Domizio P, Phillips RKS. *Lancet* 1989; ii: 783-785.
4. Cancer and the Peutz-Jeghers syndrome. Spigelman AD, Murday V, Phillips RKS. *Gut* 1989; 30: 1588-1590.
5. Management of the Peutz-Jeghers patient. Spigelman AD, Phillips RKS. *J Roy Soc Med* 1989; 82: 681.
6. Pneumatosis Coli: a cause of diagnostic confusion. Spigelman AD, Williams CB, Ansell JK, Rutter KRP, Phillips RKS. *Br J Surg* 1990; 77: 155.
7. Towards decreasing the relaparotomy rate in the Peutz Jeghers syndrome: the role of peroperative small bowel endoscopy. Spigelman AD, Thomson JPS, Phillips RKS. *Br J Surg* 1990; 77: 301-302.
8. Vitamin C levels in patients with familial adenomatous polyposis. Spigelman AD, Uff CR, Phillips RKS. *Br J Surg* 1990; 77: 508-509.
9. Mutagenicity of bile and duodenal adenomas in familial adenomatous polyposis. Spigelman AD, Crofton-Sleigh C, Venitt S, Phillips RKS. *Br J Surg* 1990; 77: 878-881.
10. Upper gastrointestinal tract pathology in familial adenomatous polyposis: results from a prospective study of 102 patients. Domizio P, Talbot IC, Spigelman AD, Phillips RKS, Williams CB. *J Clin Path* 1990; 43: 738-743.
11. Screening for cancer and precancer of the oesophagus, stomach and duodenum. Spigelman AD, Phillips RKS. *Hospital Update* 1991; 17(3): 220-227.

12. Biliary bile acid profiles in familial adenomatous polyposis. Spigelman AD, Owen RW, Hill MJ, Phillips RKS. **Br J Surg** 1991; 78: 321-325.
13. Duodeno-gastric reflux and gastric adenomas: a scintigraphic study in patients with familial adenomatous polyposis. Spigelman AD, Granowska M, Phillips RKS. **J Roy Soc Med** 1991; 84: 476-478.
14. Tumours of the liver, bile ducts, pancreas and duodenum in a single patient with familial adenomatous polyposis. Spigelman AD, Farmer KCR, James M, Richman PI, Phillips RKS. **Br J Surg** 1991; 78: 979-980.
15. DNA adducts, detected by ³²P-postlabelling, in the foregut of patients with familial adenomatous polyposis and in unaffected controls. Spigelman AD, Scates DK, Venitt S, Phillips RKS. **Carcinogenesis** 1991; 12: 1727-1732.
16. An initial experience of day surgery repair of inguinal hernias. Spigelman AD. **J One-Day Surg** 1991; 1 (2): 22-23. Plus erratum in **J One-Day Surg** 1991; 1 (3): 24.
17. Colorectal cancer: new evidence for the adenoma/carcinoma sequence. Spigelman AD, Venitt S, Carter R. **Lancet** 1992; 340: 210-211.
18. Rectal polyposis as a guide to duodenal polyposis in patients with familial adenomatous polyposis. Spigelman AD, Williams CB, Phillips RKS. **J Roy Soc Med** 1992; 85: 77-79.
19. DNA adducts, detected by ³²P-postlabelling, in the intestine of rats given bile from patients with familial adenomatous polyposis and from unaffected controls. Scates DK, Spigelman AD, Phillips RKS, Venitt S. **Carcinogenesis** 1992; 13: 731-735.
20. Inguinal hernia repair. Spigelman AD. **Update** 1993; 47: 436-445.
21. Iatrogenic pancreatitis in familial adenomatous polyposis (FAP). Nugent KP, Spigelman AD, Williams CB, Phillips RKS. **Gut** 1993; 34: 1269-1270.
22. Surgical polypectomy of duodenal adenomas in familial adenomatous polyposis: experience of two European centres. Penna C, Phillips RKS, Turet E, Spigelman AD. **Br J Surg** 1993; 80: 1027-1029.
23. Pouch adenomas in patients with familial adenomatous polyposis. Nugent KP, Spigelman AD, Nicholls RJ, Talbot IC, Neale K, Phillips RKS. **Br J Surg** 1993; 80: 1620.
24. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Nugent KP, Spigelman AD, Phillips RKS. **Dis Colon & Rectum** 1993; 36: 1059-1062.
25. DNA adducts, detected by ³²P-postlabelling, in DNA treated in vitro with bile from patients with familial adenomatous polyposis and from unaffected controls. Scates DK, Spigelman AD, Nugent KP, Phillips RKS, Venitt S. **Carcinogenesis** 1993; 14: 1107-1110.
26. Randomised controlled clinical trial of the effect of Sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. **Br J Surg** 1993; 80: 1618-1619.
27. Gallbladder dysplasia in patients with familial adenomatous polyposis. Nugent KP, Spigelman AD, Talbot IC, Phillips RKS. **Br J Surg** 1994; 81: 291-292.
28. Familial adenomatous polyposis: recent genetic advances. Spigelman AD. **Br J Surg** 1994; 81: 321-322.
29. Images in Clinical Medicine: Situs inversus. Spigelman AD. **N Eng J Med** 1994; 330: 606.
30. Evidence for adenoma-carcinoma sequence in the duodenum of patients with familial adenomatous polyposis (FAP). Spigelman AD, Talbot IC, Penna C, Nugent KP, Phillips RKS, Costello C, DeCosse JJ & The Leeds Castle Polyposis Group (Upper Gastrointestinal Committee). **J Clin Path** 1994; 47: 709-710.
31. Glutathione S-transferase mu phenotype in patients with familial adenomatous polyposis and in unaffected controls. Spigelman AD, Nugent KP, Penna C, Phillips RKS. **Cancer Det and Prev** 1994; 18 (4): 253-258.
32. Surveillance of duodenal polyps in familial adenomatous polyposis: progress report. Nugent KP, Spigelman AD, Williams CB, Talbot IC, Phillips RKS. **J Roy Soc Med** 1994; 87: 704-706.
33. For debate: Endoscopic surveillance for colorectal neoplasia. Spigelman AD. **Br J Surg** 1994; 81: 1664-5.
34. Bile acids do not form adducts when incubated with DNA *in vitro*. Scates DK, Spigelman AD, Venitt S. **Carcinogenesis** 1994; 15: 2945-2948.
35. Caffeine phenotyping of Cytochrome P4501A2, N-acetyltransferase, and xanthine oxidase in patients with familial adenomatous polyposis. Spigelman AD, Farmer KCR, Oliver S, Nugent KP, Bennett PN, Notarianni LJ, Dobrocky P, Phillips RKS. **Gut** 1995; 36: 251-254.
36. High pH reduces *in-vitro* DNA adduct formation by bile from patients with familial adenomatous polyposis: might antacids reduce duodenal polyposis? Scates DK, Venitt S, Phillips RKS, Spigelman

- AD. Gut 1995; 36: 918-921.
37. Appearance of artefacts when using ^{32}P -postlabelling to investigate DNA adduct formation by bile acids *in vitro*: lack of evidence for covalent binding. Scates DK, Spigelman AD, Venitt S. **Carcinogenesis** 1995; 16: 1489-1491.
 38. Familial adenomatous polyposis and the upper gastrointestinal tract. Spigelman AD. **Seminars in Colon & Rectal Surgery** 1995; 6: 26-28.
 39. Gall-bladder agenesis and associated congenital anomalies. Yiangou C, Shorey B, Spigelman AD. **HPB Surgery** 1995; 8: 253-255.
 40. Undergraduate surgery - coping with change. Spigelman AD. **Med Ed** 1995; 5: 7.
 41. Prise en charge des patients a risque de cancer colorectal hereditaire. (Management of patients at risk of hereditary colorectal cancer). Spigelman AD. **Acta Endoscopica** 1995; 25: 63-70.
 42. Upper intestinal surveillance in Familial Adenomatous Polyposis. Debinski HS, Spigelman AD, Hatfield A, Williams CB, Phillips RKS. **Eur J Cancer** 1995; 31A: 1149-1163.
 43. Photodynamic therapy for polyps in familial adenomatous polyposis - a pilot study. Mlkvy P, Messman H, Debinski H, Regula J, Conio M, MacRobert A, Spigelman A, Phillips R, Bown SG. **Eur J Cancer** 1995; 31A: 1160-1165.
 44. Polyposis: The Peutz-Jeghers Syndrome. Spigelman AD, Arese P, Phillips RKS. **Br J Surg** 1995; 82: 1311-1314.
 45. DNA ploidy on cytological and tissue sections of breast lumps: a comparison using image analysis. Sarker SK, Mendiola R, Spigelman AD, Walker M, Coleman DV. **Anal Quant Cytol Histol** 1996; 18: 19-22.
 46. p53 expression in duodenal tumours in patients with familial adenomatous polyposis. Kashiwagi H, Spigelman AD, Talbot IC, Phillips RKS. **Br J Surg** 1996; 83: 225-228.
 47. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Nugent KP, Spigelman AD, Phillips RKS. **Dis Colon & Rectum** 1996; 39: 659-662.
 48. Risk of extracolonic cancer in familial adenomatous polyposis. Nugent KP, Spigelman AD, Phillips RKS. **Br J Surg** 1996; 83: 1121-1122.
 49. Differences in the levels and pattern of DNA-adduct labelling in human cell lines MCL-5 and CCRF, proficient or deficient in carcinogen-metabolism, treated *in vitro* with bile from familial adenomatous polyposis patients and from unaffected controls. Scates DK, Spigelman AD, Phillips RKS, Venitt S. **Carcinogenesis** 1996; 17: 707-713.
 50. Colorectal polyp counts and cancer risk in familial adenomatous polyposis. Debinsky HS, Neale K, Love S, Spigelman AD, Phillips RKS. **Gastroenterology** 1996; 110: 1028-1030.
 51. Can we safely delay or avoid prophylactic colectomy in familial adenomatous polyposis? Phillips RKS, Spigelman AD. **Br J Surg** 1996; 83: 769-770.
 52. A modifying locus for familial adenomatous polyposis may be present on chromosome 1p35-p36. Tomlinson IPM, Neale K, Talbot IC, Spigelman AD, Williams CB, Phillips RKS, Bodmer WF. **J Med Genet** 1996; 33: 268-273.
 53. The use of ^{32}P -postlabelling in studies of the nature and origin of DNA adducts formed by bile from patients with familial adenomatous polyposis and from normal patients. Scates DK, Spigelman AD, Phillips RKS, Venitt S. **Mutation Research** 1997; 387:113-125.
 54. Screening modalities in Familial Adenomatous Polyposis and Hereditary Non-Polyposis Colorectal Cancer. Spigelman AD. **Gastrointestinal Endoscopy Clinics of North America** 1997; 7: 81-86.
 55. p53 and k-ras status in duodenal adenomas in Familial Adenomatous Polyposis. Kashiwagi H, Spigelman AD, Talbot IC, Debinski HS, McKie AB, Lemoine NR, Phillips RKS. **Br J Surg** 1997; 84: 826-829.
 56. Nuclear DNA content of fine needle aspirates of invasive ductal carcinomas of the breast. Sarker S, Spigelman A, Walker M, Coleman D. **Analytical Cellular Pathology** 1997; 13: 1-8.
 57. Peutz-Jeghers' Disease: most, but not all, families are compatible with linkage to 19p13.3. Olschwang S, Markie D, Seal S, Neale K, Phillips R, Cottrell S, Ellis I, Hodgson S, Zauber P, Spigelman A et al. **Journal of Medical Genetics** 1998; 35(1): 42-44.
 58. Malignant change in a duodenal adenoma in familial adenomatous polyposis: report of a case. Nakatsubo N, Kashiwagi H, Okumura M, Kamoshida T, Takahashi A, Spigelman AD. **American Journal of Gastroenterology** 1998; 93:1566-1568.
 59. Duodenal Polyposis in Familial Adenomatous Polyposis. Spigelman AD. **Scand J Gastro** 1999; 34: 545.
 60. Large bowel cancer: guidelines and beyond. Thomas R, Spigelman A, Armstrong B. **Med J Aust** 1999; 171: 284-285.

61. Does more equal less or does less equal more? Spigelman AD. **J Qual Clin Practice** 2000; 20: 55.
62. A survey of surgical audit in Australia: whither clinical governance? Eno LM, Spigelman AD. **J Qual Clin Practice** 2000; 20: 2-4.
63. An audit of open and laparoscopic inguinal hernia repair. Eno LM, Spigelman AD. **J Qual Clin Practice** 2000; 20: 56-59.
64. Gastroduodenal Lesions in Familial Adenomatous Polyposis. Kashiwagi H, Spigelman AD. **Surg Today** 2000; 30: 675-682.
65. Hereditary Non Polyposis Colorectal Cancer in 95 families: Differences and Similarities between Mutation-Positive and Mutation-Negative Kindreds. Scott RJ, McPhillips M, Meldrum CJ, Fitzgerald PE, Adams K, Spigelman AD, du Saret D, Tucker K, Kirk J & the Hunter Family Cancer Service. **Am J Hum Genet** 2001; 68: 118-127.
66. Relationship between APC Genotype, Polyp Distribution and Oral Sulindac Treatment in the Colon and Rectum of Patients with Familial Adenomatous Polyposis. Guldenschuh I, Hurlimann R, Muller A, Ammann R, Mullhaupt B, Dobbie Z, Gian-Franco Z, Flury R, Seelentag W, Roth J, Myenberger C, Fried M, Hoppeler T, Spigelman AD, Scott RJ. **Dis Colon & Rectum** 2001; 44: 1090-99.
67. Familial Adenomatous Polyposis: more evidence for disease diversity and genetic heterogeneity. Scott RJ, Meldrum C, Crooks R, Spigelman AD, Kirk J, Tucker K, Koorey D, the Hunter Cancer Family Service. **Gut** 2001; 48: 508-514.
68. The intention to hasten death: a survey of attitudes and practices of surgeons in Australia. Douglas CD, Kerridge IH, Rainbird KJ, McPhee JR, Hancock L, Spigelman AD. **Med J Aust** 2001; 175: 511-515.
69. Randomized Placebo-controlled Trial of Gastric Acid-Lowering Therapy on Duodenal Polyposis and Relative Adduct Labeling in Familial Adenomatous Polyposis. Wallace MH, Forbes A, Beveridge IG, Spigelman AD, Hewer A, Venitt S, Phillips RKS. **Dis Colon & Rectum** 2001; 44: 1585-1589.
70. Preventive Measures in Peutz-Jeghers syndrome. McGrath DR, Spigelman AD. **Family Cancer** 2001; 1 (2): 121-5.
71. Prevention of orthopaedic wound infections – a quality improvement project. Swan J, Douglas P, Asimus M, Spigelman AD. **J Qual Clin Practice** 2001; 21: 149-153.
72. Duodenal cancer in patients with Familial Adenomatous Polyposis – results of a 10 year prospective study. Groves CG, Saunders BP, Spigelman AD, Phillips RKS. **Gut** 2002; 50: 636-641.
73. Gastrointestinal Surgery. Spigelman AD, McGrath DR, Levy RD. **Med J Aust** 2002; 175: 15.
74. Inhibition of proliferation of a colon cancer cell line by Indole-3-Carbinol. Frydoonfar H, McGrath DR, Spigelman AD. **Colorectal Disease** 2002; 4: 205-207.
75. Clinical Perspectives: Hereditary Colorectal Cancer: keeping it in the family – the bowel cancer story. McGrath DR, Spigelman AD. **Internal Medicine** 2002; 32: 325-330.
76. A novel strategy to stop cigarette smoking in surgical patients. Haile MJ, Wiggers JH, Spigelman AD, Knight J, Considine RJ, Moore K. **ANZ J Surg** 2002; 72: 618-622.
77. Hereditary Colorectal Cancer: Selected Internet Viewings. McGrath DR, Spigelman AD. **Ann R Coll Surg Engl** 2002; 84: 218.
78. Adverse events in surgical patients in Australia. Kable A, Gibberd R, Spigelman AD. **Int J Quality in Health Care** 2002; 14: 269-276.
79. Impact of microsatellite testing and mismatch repair protein expression on the clinical interpretation of genetic testing in hereditary nonpolyposis colorectal cancer. Ward R, Meldrum C, Williams R, Molkany E, Scott R, Turner J, Hawkins N, Spigelman A. **J Cancer Res and Clin Oncology** 2002; 128: 403-411.
80. Mutation analysis of the STK11/LKB1 gene and clinical characteristics of an Australian series of Peutz-Jeghers syndrome patients. Scott RJ, Crooks R, Meldrum CJ, Thomas L, Smith CJA, Mowat D, McPhillips M, Spigelman AD. **Clinical Genetics** 2002; 62: 282-287.
81. Familial Adenomatous Polyposis and Duodenal Lymphoma: report of a case. Frizelle FA, Hemmings CT, Whitehead MR, Spigelman AD. **Dis Colon & Rectum** 2003; 12: 1698-1701.
82. The variable effect on proliferation of a colon cancer cell line by the citrus fruit flavanoid Naringenin. FrydoonFar H, McGrath DR, Spigelman AD. **Colorectal Disease** 2003; 5: 149-152.
83. The effect of Indole-3-Carbinol and sulforaphane on a prostate cancer cell line. FrydoonFar H, McGrath DR, Spigelman AD. **ANZ J Surg** 2003; 73: 154-156.
84. Overview of the National Colorectal Cancer Care Survey - Australian Clinical Practice in 2000. McGrath DR, Spigelman AD. **Colorectal Disease** 2003; 5: 588-589.
85. Audit of surgeon awareness of readmissions with venous thrombo-embolism. Swan J, Spigelman AD. **Internal Medicine** 2003; 33: 578-580.

86. Titanic waiting lists - what lies beneath? Spigelman AD. **ANZ J Surg** 2003; 73: 781.
87. Why are we waiting? Spigelman AD. **ANZ J Surg** 2003; 73: 873.
88. Measuring clinical audit and peer review practice in a diverse health care setting. Spigelman AD, Swan JR. **ANZ J Surg** 2003; 73: 1041-1043.
89. Sulforaphane inhibits growth of a colon cancer cell line. Frydoonfar H, McGrath DR, Spigelman AD. **Colorectal Disease** 2004; 6: 28-31.
90. Hereditary non-polyposis colorectal cancer and the role of hPMS2 and hEXO1 mutations. Thompson E, Meldrum CJ, Crooks R, McPhillips M, Thomas L, Spigelman AD, Scott RJ. **Clinical Genetics** 2004; 65: 215-225.
91. Management of colorectal cancer patients in Australia: the National Colorectal Cancer Survey. McGrath DR, Leong DC, Armstrong BK, Spigelman AD. **ANZ J Surg** 2004; 74: 55-64.
92. Extracolonic Polyposis in Familial Adenomatous Polyposis (FAP): So Near and Yet So Far. Spigelman AD. **Gut** 2004; 53: 322.
93. Complications after discharge for surgical patients. Kable A, Gibberd R, Spigelman AD. **ANZ J Surg** 2004; 74: 92-97.
94. Is there a link between work related stress and colorectal cancer? Spigelman AD, Dwyer P. **Med J Aust** 2004; 180: 339-340.
95. Relative frequency and morphology of cancers in *STK11* mutation carriers. Lim W, Olschwang S, Keller JJ, Westerman AM, Menko FH, Boardman LA, Scott RJ, Trimbath J, Giardiello FM, Gruber SB, Gille JJP, Offerhaus GJA, de Rooij FWM, Wilson P, Spigelman AD, Phillips RKS, Houlston RS. **Gastroenterology** 2004; 126: 1788-1794.
96. People with colorectal cancer – can we help them do better? Spigelman AD. **ANZ J Surg** 2004; 74: 401-402.
97. Germline missense changes in the APC gene and their relationship to disease. Scott RJ, Crooks R, Rose L, Attia J, Thakkinian A, Thomas L, Spigelman AD, Meldrum CJ. **Hereditary Cancer in Clinical Practice** 2004; 2: 81-91.
98. In the beginning there was colectomy: current surgical options in Familial Adenomatous Polyposis. McGrath DR, Spigelman AD. **Hereditary Cancer in Clinical Practice** 2004; 2 (4): 153-160.
99. Elective open abdominal aortic aneurysm repair: a seven year experience. Mackenzie S, Swan J, D'Este C, Spigelman AD. **Therapeutics and Clinical Risk Management** 2005; 1: 27-31.
100. The NSW & ACT Hereditary Cancer Registers. Weir L, Spigelman AD, Scott RJ, Kirk J, Zeckendorf S, Sitas F. **Aust Fam Physician** 2005; 34: 53-58.
101. A programme for reducing smoking in preoperative surgical patients: a randomized controlled trial. Wolfenden L, Wiggers J, Knight J, Campbell E, Rissel C, Kerridge R, Spigelman AD, Moore K. **Anaesthesia** 2005; 60(2): 172-9.
102. Skin antiseptics and the risk of operating theatre fires. Swan J, Spigelman AD. **ANZ J Surg** 2005; 75: 556 - 558.
103. A review of the Australian Incident Monitoring System. Spigelman AD, Swan J. **ANZ J Surg** 2005; 75: 657 - 661.
104. Mutation analysis of the *MYH* gene in an Australian series of colorectal polyposis patients with or without germline *APC* mutations. Kairupan CF, Meldrum CJ, Crooks R, Milward EA, Spigelman AD, Burgess B, Groombridge C, Kirk J, Tucker K, Ward R, Williams R, Scott RJ. **International Journal of Cancer**; 2005; 116: 73-77.
105. Increasing smoking cessation care in a preoperative clinic: a randomized controlled trial. Wolfenden L, Wiggers J, Knight J, Campbell E, Spigelman AD, Kerridge R, Moore K. **Preventive Medicine** 2005; 41: 284-290.
106. Surgeon and hospital volume and the management of colorectal cancer patients in Australia. McGrath DR, Leong DC, Gibberd R, Armstrong B, Spigelman AD. **ANZ J Surg** 2005; 41: 901-910.
107. *MLH1* germline epimutations as a factor in hereditary non-polyposis colorectal cancer. Hitchins M, Williams R, Cheong K, Halani N, Ap Lin V, Packham D, Ku S, Buckle A, Hawkins N, Burn J, Gallinger S, Goldblatt J, Kirk J, Tomlinson I, Scott R, Spigelman A, Suter C, Martin D, Suthers G, Ward R. **Gastroenterology** 2005; 129 (5): 1392-1399.
108. An interloper revealed: DNA analysis and the identification of an Egyptian Mummy. Sowada K, Matheson C, Spigelman A, Spigelman M. **Bulletin of the Australian Centre for Egyptology** 2005; 16: 101-116.
109. Surgical accountability: a framework for trust and change. Thompson A, Stonebridge PA, Spigelman

- AD. MJA 2005; 183: 500.
110. Governance and Innovation: Experience with a policy on the introduction of new interventional procedures. Spigelman AD. ANZ J Surg 2006; 76: 9-13.
 111. Frequency and spectrum of cancers in the Peutz-Jeghers Syndrome. Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJP, Keller JJ, Westerman AM, Scott RJ, Lim W, Trimbath JD, Giardiello FM, Gruber SB, Offerhaus GJA, de Rooij FWM, Wilson JHP, Hansmann A, Moslein G, Royer-Pokora B, Vogel T, Phillips RKS, Spigelman AD, Houlston RS. **Clin Cancer Res** 2006; 12(10): 3209-3215.
 112. *STK11* status and intussusception risk in Peutz-Jeghers syndrome. Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJP, Keller JJ, Westerman AM, Scott RJ, Lim W, Trimbath JD, Giardiello FM, Gruber SB, Offerhaus GJA, de Rooij FWM, Wilson JHP, Hansmann A, Moslein G, Royer-Pokora B, Vogel T, Phillips RKS, Spigelman AD, Houlston RS. **J Med Genet** 2006; 43(8): e41; doi:10.1136/jmg.2005.040535.
 113. An updated mutation spectrum in an Australian series of PJS patients provides further evidence for only one gene locus. Chow E, Meldrum CJ, Crooks R, Macrae F, Spigelman AD, Scott RJ. **Clin Genet** 2006; 70: 409-414.
 114. Concordance with national guidelines for colorectal cancer care – a population-based patterns of care study of 3,095 patients. Young J, Leong D, Armstrong K, O’Connell D, Armstrong B, Spigelman A, Chapuis P, Kneebone A, Solomon M. **MJA** 2007; 186: 292-296.
 115. Disseminating Risk Information to Familial Adenomatous Polyposis Families. Groombridge C, Burgess B, Sitas F, Spigelman AD, Weir L. **Familial Cancer** 2007; 6: 323-324.
 116. Pathology reporting of resected colorectal cancers in New South Wales in 2000. Chapuis PH, Chan C, Lin BPC, Armstrong K, Armstrong B, Spigelman AD, O’Connell D, Leong D, Dent OF. **ANZ J Surg** 2007; 77: 963-969.
 117. Putative mechanisms of action for indole-3-carbinol in the prevention of colorectal cancer. McGrath DR, Spigelman AD. **Expert Opin. Ther. Targets** 2008; 12 (6): 729-738.
 118. Australian Perspectives: *Déjà vu* 4 U. Spigelman AD. **Clinical Governance: An International Journal**. 2008; 13 (2): 147-148.
 119. Measurement for improvement: a survey of current practice in Australian public hospitals. Brand CA, Tropea J, Ibrahim JE, Elkadi SO, Bain CA, Ben-Tovim DI, Bucknall TK, Greenberg PB, Spigelman AD. **MJA** 2008; 189: 35-40.
 120. Australian Perspectives: Clinical Governance Units in New South Wales, Australia. Spigelman AD. **Clinical Governance: An International Journal**. 2008; 13 (3): 225-6.
 121. Predictors of adverse events in surgical admissions in Australia. Kable A, Gibberd R, Spigelman AD. **Int J Quality in Health Care** 2008; doi: 10.1093/intqhc/mzn032.
 122. Measuring compliance with surgical antibiotic protocols: an intervention. Kable A, Gibberd R, Spigelman AD. **Clinical Governance: An International Journal**. 2008; 13 (4): 296-304. Article URL: <http://www.emeraldinsight.com/10.1108/14777270810912996>
 123. A randomized trial of a breast/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling. Wakefield CE, Meiser B, Homewood J, Taylor A, Gleeson M., Williams R., the AGenDA Collaborative Group (Spigelman A, Member) and Tucker K. **Psycho-Oncology** special issue entitled 'Genetic testing for cancer risk'; 2008; 17(8):844-54. Impact Factor: 2.322. Tier: B.
 124. A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk. Wakefield CE, Meiser B, Homewood J, Peate M, Taylor A, Lobb E, Kirk J, Young M., Williams R, Dudding T, Tucker K, and the AGenDA Collaborative Group (Spigelman A, Member). **Breast Cancer Research and Treatment**; 2008; 107: 289-301. Impact Factor: 4.67 (JCR: 2006). Tier: A.
 125. A randomized trial of a decision aid for individuals considering genetic testing for hereditary non-polyposis colorectal cancer risk. Wakefield CE, Meiser B, Homewood J, Ward R, O'Donnell S, Kirk J, and the AGenDA Collaborative Group (Spigelman A, Member). **Cancer**; 2008; 113(5):956-965. Impact Factor: 4.800 (JCR: 2007). Tier: A.
 126. Providing comprehensive smoking cessation care to surgical patients: the case for computers. Wolfenden L, Wiggers J, Campbell E, Knight J, Kerridge R, Spigelman A. **Drug and Alcohol Review** 2009; 28: 60-65.
 127. MTHFR 677 C>T and 1298 A>C polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer. Reeves SG, Meldrum C, Groombridge C, Spigelman AD, Suchy J,

- Kurzwaski G, Lubinski J, McElduff P, Scott RJ. *European Journal of Human Genetics* 2009; 17(5):629-35.
128. Haemochromatosis HFE gene polymorphisms as potential modifiers of hereditary nonpolyposis colorectal cancer risk and onset age. Shi Z, Johnstone D, Talseth-Palmer BA, Evans TJ, Spigelman AD, Groombridge C, Milward EA, Olynyk JK, Suchy J, Kurzwaski G, Lubinski J, Scott RJ. *Int J Cancer*; 2009; 125(1):78-83.
129. Adverse events in five surgical procedures. Kable A, Gibberd R, Spigelman AD. *Clinical Governance: An International Journal*. 2009; 14 (2): 145-55.
130. Psychosocial impact of Familial Adenomatous Polyposis on young adults: a qualitative study. Meiser B, Mireskandari S, Sangster J, Thewes B, Groombridge C, Spigelman A, Andrews L. *J Genetic Counseling*; 2009; 18: 409-417.
131. Features of duodenal cancer in patients with Familial Adenomatous Polyposis. Latchford A, Clark S, Neale K, Spigelman AD, Phillips RKS. *Clinical Gastroenterology and Hepatology* 2009; 7: 659-663.
132. Clinical Outcome Information: the patient Patient. Spigelman AD. *Clinical Governance: An International Journal*. 2009; 14 (3): 245-247.
133. Health System Reform. Spigelman AD. *Clinical Governance: An International Journal*. 2010; 15 (1): 46-49.
134. Serum Glutathione transferase does not respond to Indole-3-carbinol: a pilot study. McGrath DR, Spigelman AD. *Therapeutics and Risk Management*. 2010; 6: 225-231.
135. MSH6 and PMS2 mutation positive Australian Lynch Syndrome families: novel mutations, cancer incidence and age of diagnosis of colorectal cancer. Talseth-Palmer BA, McPhillips M, Groombridge C, Spigelman A, Scott RJ. *Hereditary Cancer in Clinical Practice* 2010; 8: 5 <http://www.hccpjournals.com/content/8/1/5>
136. Attenuated familial adenomatous polyposis: results from an international collaborative study. Knudsen AL, Bülow S, Tomlinson I, Möslin G, Heinimann K, Christensen IJ; AFAP Study Group (including A Spigelman). *Colorectal Dis*. 2010 Oct;12(10 Online):e243-9. doi: 10.1111/j.1463-1318.2010.02218.x.
137. Can a Familial Gastrointestinal Tumour Syndrome be allelic with Waardenburg Syndrome? Vilain RE, Dudding T, Braye SG, Groombridge C, Meldrum C, Spigelman AD, Ackland S, Ashman L, Scott RJ. *Clin Genet*. 2011 Jun;79(6):554-60. doi: 10.1111/j.1399-0004.2010.01489.x.PMID: 20636395
138. Colorectal cancer susceptibility loci on chromosome 8q23.3 and 11q23.1 as modifiers for disease expression in Lynch syndrome. Talseth-Palmer BA, Brenne IS, Ashton KA, Evans TJ, McPhillips M, Groombridge C, Suchy j, Kurzwaski G, Lubinski J, Spigelman A, Scott RJ. *J Med Genet*. 2010 Dec 8. [Epub ahead of print] PMID: 21097774 [PubMed - as supplied by publisher]. 079962Published Online First: 19 November 2010 doi:10.1136/jmg.2010.079962. *J Med Genet* 2011; 48: 279-284.
139. Targeted Prostate Cancer Screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the Impact Study. Mitra AV, A Spigelman et al. *BJU Int*. 2011 Jan; 107 (1):28-39. doi: 10.1111/j.1464-410X.2010.09648.x. Epub 2010 Sep 14. PMID: 20840664
140. Cancer survival in Australia, Canada, Denmark, Norway, Sweden and the UK, 1995-2007: the International Cancer Benchmarking Partnership. Coleman MP and the ICBP Module 1 Working Group (including A Spigelman). *Lancet*. www.thelancet.com Published online December 22, 2010 DOI:10.1016/S0140-6736(10)62231-3. 2011; 377: 127-138.
141. Clinical governance: a review of key concepts in the literature. Travaglia JF, Debono D, Spigelman AD, Jeffrey Braithwaite J. *Clinical Governance: An International Journal* 2011; 16 (1): 62 – 77.
142. New governments: new policies. Spigelman AD. *Clinical Governance: An International Journal*. 2011; 16 (3): 250-251.
143. Are videoconferenced consultations as effective as face-to-face consultations for hereditary breast/ovarian cancer genetic counseling? Zilliacus EM, Meiser B, Lobb EA, Kelly PJ, Barlow-Stewart K, Kirk JA, Spigelman AD, Warwick LJ, Tucker KM. *Genetics in Medicine* 2011; 13 (11): 933-941.
144. DNA repair gene polymorphisms and risk of early onset colorectal cancer in Lynch syndrome. Reeves SG, Meldrum C, Groombridge C, Spigelman A, Suchy J, Kurzwaski G, Lubinski J, Scott RJ. *Cancer Epidemiol*. 2012 Apr; 36(2):183-9. Epub 2011 Oct 5.
145. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV,

- Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen HF, Barker G, Crawford G, Elliott F, Movahedi M, Pylvanainen K, Wijnen JT, Fodde R, Lynch HT, Mathers JC, Bishop DT; CAPP2 Investigators. Collaborators: Ball J, Baxter L, Boussioutas A, Bradshaw N, Brewer C, Broughton M, Bulman B, Castiglione M, Clark S, Ching R, Chu C, Cina S, Cook J, Cummings C, Davies R, Debniaik T, de Moncuit C, Drummond S, Ellis T, Fidalgo P, Gallinger S, Goff S, Goldberg PA, Goodman S, Harocopos C, Hutter P, Jeffers L, Jordan S, Killick P, Krauss C, Kristensen J, Langman C, Leite J, Liljegren A, Olini C, Marks C, Membrez-Antonioli V, Miller J, Miles T, Segura PP, Pichert G, Pietersen E, Rossi G, Sala P, Sampson J, Schmock B, Shaw J, Spigelman A, Tempesta A, Velthuisen M, Walpole I, Kerr D, Perkins S, Cuzick J, Wood LF, Steele R, Altman D, Paraskeva C, Atkin W, Hull M. **Lancet**. 2011 Dec 17; 378(9809):2081-7. doi: 10.1016/S0140-6736(11)61049-0. Epub 2011 Oct 27.
146. Patients with colorectal cancer: A qualitative study of referral pathways and continuing care. Harris MF, Pascoe S, Crossland L, Beilby J, Veitch C, Spigelman A, Weller D. *Australian Family Physician* 2012; 41: 899-902.
147. Is colorectal surveillance indicated in patients with the PTEN hamartoma tumor syndrome? Marry H. Nieuwenhuis, C. Marleen Kets, Maureen Murphy-Ryan, Chrystelle Colas, Pal Möller, Frederik J. Hes, Shirley V. Hodgson, Maran J.W. Olderode-Berends, Stefan Aretz, Karl Heinemann, Encarna B. Gomez Garci, Judith Goodship, Allan Spigelman, Susanne Timshel, Noralane M. Lindor, Hans F.A. Vasen. **Colorectal Disease**; 2012 Sep; 14(9):e562-6. doi: 10.1111/j.1463-1318.2012.03121.x. PMID:22672595
148. Patient safety teaching in Australian medical schools: a national survey. Allan D Spigelman, Deborah S Debono, Kim Oates, Adam G Dunn, Jeffrey Braithwaite. **Clinical Risk** 2012; 18(2): 46-51.
149. Socio-demographic and other patient characteristics associated with time between colonoscopy and surgery, and choice of treatment centre for colorectal cancer: a retrospective cohort study. Goldsbury D, Harris MF, Pascoe S, Olver I, Barton M, Spigelman A, O'Connell D. **BMJ Open** 2012; 2: e001070. doi:10.1136/bmjopen-2012-001070
150. Long-term effect of resistant starch on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Mathers JC, Movahedi M, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans G, Maher ER, Bertario L, Bisgaard ML, Dunlop M, Ho JW, Hodgson S, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar R, Side L, Scott RJ, Thomas HJ, Vasen H, Gerdes AM, Barker G, Crawford G, Elliott F, Pylvanainen K, Wijnen J, Fodde R, Lynch H, Bishop DT, Burn J; CAPP2 Investigators. Collaborators: Ball J, Baxter L, Boussioutas A, Bradshaw N, Brewer C, Broughton M, Bulman B, Castiglione M, Clark S, Ching R, Chu C, Cina S, Cook J, Cummings C, Davies R, Debniaik T, de Moncuit C, Drummond S, Ellis T, Fidalgo P, Gallinger S, Goff S, Goldberg PA, Goodman S, Harocopos C, Hutter P, Järvinen H, Jeffers L, Jordan S, Killick P, Krauss C, Kristensen J, Langman C, Leite J, Liljegren A, Olini C, Marks C, Membrez-Antonioli V, Miller J, Miles T, Segura PP, Pichert G, Pietersen E, Rossi G, Sala P, Sampson J, Schmock B, Shaw J, Spigelman A, Tempesta A, Velthuisen M, Walpole I. **Lancet Oncol**. 2012 Dec; 13(12):1242-9. doi: 10.1016/S1470-2045(12)70475-8. Epub 2012 Nov 7.
151. Combined analysis of three Lynch syndrome cohorts confirms the modifying effects of 8q23.3 and 11q23.1 in MLH1 mutation carriers. Bente A. Talseth-Palmer, Juul T. Wijnen, Ingvild S. Brenne, Shantie Jagmohan-Changur, Daniel Barker, Katie A. Ashton, Carli M. Tops, Tiffany-Jane Evans, Mary McPhillips, Claire Groombridge, Janina Suchy, Grzegorz Kurzawski, The Dutch Cancer Genetics Group, Allan Spigelman, Pal Moller, Hans M. Morreau, Tom Van Wezel, Jan Lubinski, Hans F. A. Vasen, Rodney J. Scott. **Int J Cancer** 2013; 132(7): 1556-64. Sep 14. doi: 10.1002/ijc.27843. [Epub ahead of print]
152. Stage at diagnosis and colorectal cancer survival in six high-income countries: A population-based study of patients diagnosed during 2000 – 2007. Maringe C, et al, Spigelman A The ICBP Module 1 Working Group. **Acta Oncologica** 2013; 52 (5): 919-32.
153. The varying role of the GP in the pathway between colonoscopy and surgery for colorectal cancer: a retrospective cohort study. Goldsbury D, Harris M, Pascoe S, Barton M, Olver I, Spigelman A, Bielby J, Veitch C, Weller D, O'Connell D. **BMJ Open** 2013 Mar 6; 3(3). pii: e002325. doi: 10.1136/bmjopen-2012-002325. 2013.
154. Continuing difficulties in interpreting CNV data: Lessons from a genome-wide CNV association study of Australian HNPCC/Lynch syndrome patients. Talseth-Palmer BA, Holliday EG, Evans TJ, McEvoy M, Attia J, Grice DM, Masson AL, Meldrum C, Spigelman AD, J Scott RJ. **BMC Medical Genomics** 2013; 6: 10 – 19. Mar 26; 6:10. doi: 10.1186/1755-8794-6-10.

155. Referral pathways in colorectal cancer: an audit of surgeons' records. Spigelman AD, Pascoe SW, Harris MF, Bielby JJ, Crossland LJ, Gett RM, Barton MB, Jayasinghe UW. **Australian Health Review** 2013 <http://dx.doi.org/10.1071/AH13038>.
156. Case Report: Metachronous central nervous system desmoid tumours and thyroid carcinoma in a young Familial Adenomatous Polyposis patient. Butel-Simoes G, Spigelman AD. **Familial Cancer** 2013; 12 (4): 647-649.
157. Patients' experiences of referral for colorectal cancer. Shane W Pascoe, Craig Veitch, Lisa J Crossland, Justin J Beilby, Allan Spigelman, John Stubbs and Mark F Harris. **BMC Family Practice** 2013; 14: 124 (26 Aug 2013).
158. The importance of a large sample cohort for studies on modifier genes influencing disease severity in FAP patients. Talseth-Palmer BA, Wijnen JT, Andreassen EK, Barker D, Jagmohan-Changur S, Tops CM, Meldrum C, Spigelman A, Hes FJ, Van Wezel T, Vasen HF, Scott RJ. **Hereditary Cancer in Clinical Practice** 2013; 11: 20 - 30.
159. Targeted prostate cancer screening in *BRCA1* and *BRCA2* mutation carriers: results from the initial screening round on the IMPACT study. Bancroft EK, Page EC, Castro E et al, Spigelman A, Eeles R. **Eur Urol** 2014; 66 (3), 489-99 <http://dx.doi.org/10.1016/j.eururo.2014.01.003>
160. Cancer risk and genotype-phenotype correlations in *PTEN* hamartoma tumor syndrome. Nieuwenhuis MH, Kets CM, Murphy-Ryan M, Yutema HG, Evans DG, Colas C, Muller P, Hes FJ, Hodgson SV, Olderode-Berends MJW, Aretz S, Heinemann K, Gomes Garcia EB, Douglas F, Spigelman A, Timshel S, Lindor N, Vasen HA. **Familial Cancer** 2014; 13: 57-63.
161. Attitudes and knowledge of medical practitioners to hereditary cancer clinics and cancer genetic testing. Teng I, Spigelman A. **Familial Cancer** 2014; 13(2): 311-324.
162. Analysis of patient reports on the referral process to two NSW cancer genetic services. Butel-Simoes GI, Spigelman AD. **Familial Cancer** 2014; 13 (3): 333-343.
163. The impact of genomics on the future of medicine and health. Mattick JS, Dziadek M, Terrill BN, Kaplan W, Spigelman AD, Bowling FG, Dinger ME. **MJA** 2014; 201: 17-20.
164. Clinical and pathologic features of familial pancreatic cancer. Humphris JL, Johns AL, Simpson SH, Spigelman AD et al. **Cancer** 2014; 120 (23): 3669-3675.
165. Clinical Governance in Australia. Rendalls S, Spigelman AD. **Clinical Governance: An International Journal** 2015; 20 (2): 56-73.
166. Targeted next-generation sequencing identifies two Lynch syndrome families and a polygenic interaction that may cause cancer development in a third Lynch syndrome family. Talseth-Palmer BA, Bauer DC, Sjursen W, Evans TJ, McPhillips M, Proietto A, Otton G, Spigelman AD, Scott RJ. **Cancer Medicine** 2016; <http://onlinelibrary.wiley.com/doi/10.1002/cam4.628/epdf>. On Line version January 2016.
167. Copy number variants associated with 18p11.32, DCC and the promoter 1B region of APC in colorectal polyposis patients. Masson AL, Talseth-Palmer BA, Evans TJ, McElduff P, Spigelman AD, Hanna GN, Scott RJ. **Meta Gene** 2016; 7: 95-104.
168. Antimicrobial Stewardship: Australia. Spigelman AD, Rendalls S, McLaws M-L, Grey A. **International Journal of Health Governance** 2016; 21(3): 139-149. <http://www.emeraldinsight.com/doi/pdfplus/10.1108/IJHG-02-2016-0010>.
169. Management of Polyposis Patients. Spigelman AD. **ANZ J Surg** 2017; 87: 427-429. DOI 10.1111/ans.13941
170. Thyroid cancer in a patient with Lynch syndrome – case report and literature review. Fazekas-Lavu M, Parker A, Spigelman AD, Scott RJ, Epstein R, Jensen M, Samaras K. **Therapeutics and Clinical Risk Management** 2017; 13: 915-918. <https://doi.org/10.2147/TCRM.S121812>
171. Cancer multidisciplinary team meetings in practice: Results from a multi-institutional quantitative survey and implications for policy change. Rankin N, Lai M, Miller D, Beale P, Spigelman A, Prest G, Turley K, Simes J. **Asia-Pacific Journal of Clinical Oncology** 2018; 14: 74-83 DOI: 10.1111/ajco.1275
172. Prostate-specific antigen velocity as a predictive biomarker in a prospective prostate cancer screening study of men with genetic predisposition. Mikropoulos C, Selkirk CG, Saya S, Bancroft E, et al. Spigelman A, et al Eeles RA. **British Journal of Cancer** 2018; 118: 266-276.
173. Kable A, Spigelman AD. Why clinicians involved with adverse events need much better support. **International Journal of Health Governance** 2018; 23 (4): 312-315.
174. Adherence to referral guidelines: genetic testing in an Australian triple negative breast cancer (TNBC) cohort. Lu M, Spigelman AD. **International Journal of Health Governance** 2019; 24 (1): 6-18 <https://doi.org/10.1108/IJHG-09-2018-0045>.

175. Low-level parental mosaicism in an apparent de novo case of Peutz-Jeghers syndrome. Butel-Simoes GI, Spigelman AD, Scott RJ, Vilain RE. **Familial Cancer** 2019; 18: 109-112. <https://doi.org/10.1007/s10689-018-0093-3>.
176. Adherence to guidelines for the referral of patients with colorectal cancer and abnormal tumour tissue testing for assessment for Lynch Syndrome. Han J, Spigelman AD. **ANZ J Surg** 2019; 89: doi: 10.1111/ans.15054
177. Outcomes of universal germline testing for men with prostate cancer in an Australian tertiary centre. Crumbaker M, Wong J, Joshua AM, Spigelman A. **Asia Pac J Clin Onco**. 2019; 15: 257–261. (DOI) - 10.1111/ajco.13148.
178. Nutritional predictors of hospital admissions in patients being treated for head and neck cancer. Duffy AM, Halaki M, Spigelman A, Venessa Chin V, Gallagher RM, Flood VM. **Supportive Care in Cancer** <https://doi.org/10.1007/s00520-019-04826-w>. Access via <https://rdcu.be/bzZuj> published on line 2 May 2019.
179. NTHL1-Associate polyposis: First Australian Case Report. Groves A, Gleeson M, Spigelman AD. **Familial Cancer**. <https://doi-org.wwwproxy1.library.unsw.edu.au/10.1007/s10689-018-0107-1> First Online 11 March 2019 DOI <https://doi-org.wwwproxy1.library.unsw.edu.au/10.1007/s10689-018-0107-1> Publisher Name Springer Netherlands Print ISSN 1389-9600 Online ISSN 1573-7292
180. Personalised risk assessment and the role of genetic testing in a prospective Australian pancreatic cancer screening program. Dwarte TM, McKay S, Johns A, Tucker K, Spigelman A, Williams D, Stoita A. **Familial Cancer** submitted 2019
181. Celebrating the career and contributions of Dr Henry T Lynch (1928-2019). Butel-Simoes G, MacRae F, Spigelman AD. **Internal Medicine** 2019 in press.

OTHER PUBLICATIONS

1. Breast Disease. Spigelman AD. **Regional Therapeutic News** July 1995, No 8.
2. Training of overseas doctors in the United Kingdom. Spigelman A. **Surgery** (Scalpel) 1995; 13 (5): 2-3.
3. Hereditary Bowel Cancer: Prevention is Better Than Cure. Spigelman AD. **Cancer Council Professional Update** August 1998.
4. Surgical Adverse Events Study. Kable AK, Gibberd RW, Spigelman AD. **Report to the NSW Ministerial Advisory Committee for Quality in Health Care**. 1999.
5. Clinical Practice Guidelines. Familial Aspects of Cancer: A guide to clinical practice. NHMRC, Canberra 1999 (member of Working Party).
6. What a difference a day can make. Same Day Surgical and Endoscopic Procedures Policy. NSW Health, 1999 (member of Reference Group).
7. New Initiatives for Conjoint Staff. Spigelman A. **J Med and Health Sci Newsletter** 2001; 107: 13.
8. International Forum presents common challenges in hereditary bowel cancers. Spigelman A. **Newsletter: NSW & ACT Hereditary Bowel Cancer Registers** August 2001.
9. Anticancer Compounds in Cruciferous Vegetables. Spigelman A, McGrath D. **J Med and Health Sci Newsletter** 2002; 110: 13.
10. Hunter Area Health Service: Clinical Risk Management Framework & Patient Safety Process. Douglas P, Spigelman AD. February 2003 (1st ed.); August 2003 (2nd ed.).
11. The National Colorectal Cancer Care Survey - Australian Clinical Practice in 2000. Spigelman AD, McGrath DR. **RACS Surgical News** January / February 2003; 4(1): 15.
12. The National Colorectal Cancer Care Survey - Australian Clinical Practice in 2000. McGrath DR, Spigelman AD. **Medical Oncology Group of Australia Newsletter** March 2003, p. 7.
13. Managing Clinical Risk and Improving Patient Safety. Douglas P, Spigelman A. **J Med and Health Sci Newsletter** 2003; 116: 11.
14. Patient Care must be the top priority. Allan Spigelman. Newcastle Herald, December 26, 2003, page 9.
15. Hospital Waiting Lists. Interview with Norman Swan, **The Health Report, ABC National Radio**, December 18, 2003. Transcript available at www.abc.net.au/rn/talks/8.30/helthrpt/stories/s1010746.htm
16. Making the Health System Safer: New Interventional procedures. Spigelman A. **J Med and Health Sci Newsletter** 2004; 120: 10.
17. Measurement for Improvement Toolkit. Australian Commission on Safety and Quality in Health Care, 2006. (member of National Expert Panel – a collaborative project) ISBN 978-0-9803462-0-6

- <http://www.safetyandquality.org/internet/safety/publishing.nsf/Content/publications#toolkit>
18. Thavaneswaran P, Maddern G, Spigelman A, Baggeley C, O'Connell H. Review of Policies and Processes for the Introduction of New Interventional Procedures. ASERNIP-S Report No. 58, Adelaide, South Australia: ASERNIP-S, July 2007. ISBN 0 909844 80 1 www.surgeons.org/asernip-s/publications.htm
 19. Taking the fast track to recovery. Insight. Allan Spigelman. April 3, 2011. Australasian Medical Publishing Company.
http://www.mjainsight.com.au/view?post=Allan+Spigelman%3A+Taking+the+fast+track+to+recovery&post_id=3977&cat=comment&utm_medium=ET_email&utm_content=aspigelman@stvincents.co.m.au&utm_campaign=April-3-2011_b2c_20110404_newsletter&utm_source=b2c_20110404_newsletter&utm_term=
 20. Angelina lifts the lid on genetic screening. Professor Allan Spigelman. Newcastle Herald, May 16, 2013.

VIDEOS

1. Interviewing techniques for interviewers. **Royal Australasian College of Surgeons**. 1998
2. Under Wraps: an autopsy of three Egyptian Mummies. **Astarte Resources**. 1998
3. Science Frontiers 3 – Ancient Autopsies. **Beyond Productions**. 2000
4. Essentials of Physical Examination of the Abdomen. **University of Newcastle Audio-Visual Centre**. 2002
5. The Upper Gastrointestinal Tract. Royal College of Physicians, London, 2018.
<https://aischannel.com/conference/st-marks-the-upper-gi-tract/>

BOOK REVIEWS

1. Management of Colorectal Cancer. (Eds.) H. Bleiberg, P. Rougier and H-J Wilke. Martin Dunitz (1998). **Cancer Forum** 1998; 22 (3): 20.
2. Textbook of Surgery. (Eds.) GJA Clunie, J Tjandra, DMA Francis. Blackwell Scientific Asia (1999). **Med J Aust** 1999; 170: 137.
3. 20 Common Problems. Surgical Problems and Procedures in Primary Care. (Eds) Lynge DC, Weiss BG. New York: McGraw-Hill 2001. **Med J Aust** 2001; 175: 489.
4. Minimally Invasive Cancer Management. (Eds.) F L Greene, Heniford BT. Springer (2001). **Cancer Forum** 2001; 25 (3): 176.
5. Inherited Cancer Syndromes – Current Clinical Management. C Neal Ellis (Ed.) 2004, Springer Germany. **ANZ J Surg** 2004; 74: 1035.
6. Terminal decline: A surgeon's diagnosis of the Australian health-care system. Reviewed by Allan D Spigelman. **Med J Aust** 2011; 194 (6): 322.
http://www.mja.com.au/public/issues/194_06_210311/spi041_bookreview_fm.html

LETTERS

1. The functional result of pelvic ileal reservoir in 10 patients with familial adenomatous polyposis. Spigelman AD, Phillips RKS. **Ann R Coll Surg Eng** 1989; 71: 269.
2. Genes and carcinogens. Spigelman AD, Phillips RKS, Venitt S. **Lancet** 1989; ii: 1210.
3. Association of congenital hypertrophy of the retinal pigment epithelium with familial adenomatous polyposis. Spigelman AD, Phillips RKS. **Br J Surg** 1990; 77: 1195.
4. Biliary bile acid profiles in familial adenomatous polyposis authors reply. Spigelman AD, Owen RW, Hill MJ, Phillips RKS. **Br J Surg** 1992; 79: 90.
5. Bile and the growth of intestinal polyps. Spigelman AD, Venitt S, Phillips RKS. **Arch Surg** 1992; 127: 361.
6. Ileo-anal pouch procedure. Spigelman AD, Phillips RKS. **ANZ J Surg** 1992; 62: 495.
7. Duodenal cancer in polyposis patients. Spigelman AD, Jensen W, Bulow S. **Gastroenterology** 1992; 103: 1995.
8. Follow-up in familial adenomatous polyposis. Nugent KP, Spigelman AD, Williams CB, Talbot IC, Phillips RKS. **Lancet** 1993; 341: 1225.
9. Screening and management of FAP. Spigelman AD, Nugent KP, Phillips RKS. **Gut** 1993; 34: 1292.
10. Surveillance of ampullary adenomas in familial adenomatous polyposis. Kashiwagi, H, Spigelman AD, Debinski HS, Talbot IC, Phillips RKS. **Lancet** 1994; 344: 1582.
11. Colomastology as a subspeciality of surgical oncology. Spigelman AD. **Br J Surg** 1995; 82: 280.

12. Genetic susceptibility to colorectal cancer in patients under 45 years of age. Spigelman AD. **Br J Surg** 1995; 82: 423.
13. Effect of sulindac on small polyps in familial adenomatous polyposis. Debinski HS, Trojan J, Nugent KP, Spigelman AD, Phillips RKS. **Lancet** 1995; 355: 855-6.
14. Relationship between colorectal and prostate cancer. Spigelman AD. **Dis Colon & Rectum** 1995; 38: 555.
15. Faxed electronic summaries are valued by general practitioners. **BMJ** 1995; 311: 746-747.
16. Caffeine phenotyping in patients with familial adenomatous polyposis may shed light on sporadic colon cancer and acetylator status - reply. Spigelman AD, Phillips RKS. **Gut** 1996; 38: 153.
17. A missed breast cancer. Spigelman AD. **ANZ J Surg** 1996; 66: 118.
18. Polyposis: the Peutz Jeghers Syndrome. Spigelman AD, Phillips RKS. **Br J Surg** 1996; 83: 874-875.
19. Coding message. Spigelman A. **Hospital Doctor** January 16, 1997; 24.
20. Organisation of Breast Care and Teaching. Spigelman A. **J R Soc Med** 1997; 90(9): 25-26.
21. Surveillance of the duodenum in patients with familial adenomatous polyposis. Spigelman A, Phillips RKS. **Gut** 1998; 42:144-145.
22. Maybe general surgery no longer exists as a specialty. Spigelman A. **BMJ** 1998; 316: 778.
23. Assessment of a scoring system for breast imaging. Spigelman AD **Br J Surg** 1998; 85: 1722.
24. Early discharge after surgery for breast cancer. Hotel wards are good option for patients. Spigelman AD **BMJ** 1999; 318:1217.
25. Magnetic Resonance Spectroscopy and Breast Cancer: Comment. Spigelman AD. **ANZ J Surg** 1999; 69: 531.
26. Think regional. Spigelman AD. **Sydney Morning Herald** August 23, 1999.
27. Current surgical practice in screening for colorectal cancer based on family history criteria. Spigelman AD. **Br J Surg** 1999; 86: 426-427.
28. Alcohol abstinence: patient or surgeon? Spigelman AD. [www.bmj.com](http://www.bmj.com/cgi/eletters/318/7194/1311#3296). eBMJ Rapid Responses. May 25, 1999. [bmj.com/cgi/eletters/318/7194/1311#3296](http://www.bmj.com/cgi/eletters/318/7194/1311#3296).
29. Consultant surgeons' opinions of the skills required of basic surgical trainees. Spigelman AD. **Br J Surg** 2000; 87: 517.
30. Familial adenomatous polyposis: extending the role of dye spray at colonoscopy. Spigelman A. **Dis Colon Rectum** 2000; 43 (5): 726.
31. Tumour site, sex, and survival in colorectal cancer. Scott RJ, Spigelman AD. **Lancet** 2000; 356: 857.
32. Colorectal cancer gene testing utility underestimated. Spigelman AD. [www.bmj.com](http://www.bmj.com/cgi/eletters/322/7293/1052#14819). eBMJ Rapid Responses. May 29, 2001. [bmj.com/cgi/eletters/322/7293/1052#14819](http://www.bmj.com/cgi/eletters/322/7293/1052#14819).
33. Assisted dying study. Spigelman AD. [www.bmj.com](http://www.bmj.com/cgi/eletters/323/7324/1268#17844). eBMJ Rapid Responses. November 29, 2001. [bmj.com/cgi/eletters/323/7324/1268#17844](http://www.bmj.com/cgi/eletters/323/7324/1268#17844).
34. Indole-3-Carbinol: a novel anti-parasitic treatment? McGrath DR, Frydoonfar H, Spigelman AD. [www.bmj.com](http://www.bmj.com/cgi/eletters/325/7374/1221#28840) eBMJ Rapid Responses. January 21, 2003. (<http://www.bmj.com/cgi/eletters/325/7374/1221#28840>).
35. Safety and Efficacy of New Interventional Procedures. Spigelman AD. [www.bmj.com](http://www.bmj.com/cgi/eletters/326/7385/347#29634) eBMJ Rapid Responses. February 14, 2003. [bmj.com/cgi/eletters/326/7385/347#29634](http://www.bmj.com/cgi/eletters/326/7385/347#29634).
36. Is biliary pain a colic? McGrath DR, Spigelman AD. [www.bmj.com](http://www.bmj.com/cgi/eletters/325/7365/639#29909) eBMJ Rapid Responses. February 24, 2003 <http://www.bmj.com/cgi/eletters/325/7365/639#29909>.
37. Pathogenesis and clinical management of hereditary non-polyposis colorectal cancer. Spigelman AD. **Br J Surg** 2003; 90: 370.
38. What would the patient choose? McGrath DR, Spigelman AD. [www.bmj.com](http://www.bmj.com/cgi/eletters/326/7394/832) eBMJ Rapid Responses. April 23, 2003 <http://www.bmj.com/cgi/eletters/326/7394/832>.
39. Re: re: complications after discharge for surgical patients. Kable A, Gibberd R, Spigelman A. **ANZ J Surg** 2004; 74: 805.
40. Genetic testing: a round table conversation. Spigelman A, Burgess B, Groombridge C, Scott RJ. **International Med Journal** 2004; 34: 587-8.
41. Colorectal cancer site varies with age and gender. McGrath DR, Spigelman AD. **Postgraduate Medical Journal** on line, December 8, 2004 <http://pmj.bmjournals.com/cgi/eletters/80/949/667>.
42. Spigelman A, Gani J. Re: Pylorus-preserving pancreaticoduodenectomy for advanced duodenal disease in familial adenomatous polyposis (p.1157-1164). **Br J Surg** 2005; 92: 253. & **Br J Surg** 2004; online.
43. Detoxification enzymes in the duodenal mucosa of patients with familial adenomatous polyposis (p.754-755). Spigelman AD. 14 July 2005, online at <http://www.bjs.co.uk/bjsCda/cda/microViewCorrespondence.do;jsessionid=90F4F981BED74D74887B25>

- 8CD189AF3C?DOI=10.1002%2Fbjs.4996&issueDOI=10.1002%2Fbjs.v92%3A6&vid=2.
44. Re: Submission 8259, Response to 'Factors affecting morbidity, mortality and survival in patients undergoing surgery for rectal cancer in a district general hospital' by Macadam R et al. Spigelman AD. e-letter **Ann R Coll Surg Eng** April 2006; <http://www.rcseng.ac.uk/publications/eletters/>.
 45. Germline mutations of *APC* are not associated with inherited colorectal polyposis. Hitchins M, Suter C, Wong J, Cheong K, Hawkins N, Leggett B, Scott R, Spigelman A, Tomlinson I, Martin D, Ward R. **Gut** 2006; 55: 586-7.
 46. A comparison of colorectal neoplasia screening tests: a multicentre community-based study of the impact of consumer choice. Spigelman AD. **Med J Aust** 2006; 238-9.
 47. Patient Safety, Audit and Proactive Risk Assessment. Spigelman A. 29 January 2007 <http://www.bmj.com/cgi/eletters/334/7586/169>.
 48. More to the gene test row. Allan Spigelman. **Sydney Morning Herald**, October 27, 2008 <http://www.smh.com.au/letters/?page=fullpage#contentSwap2>
 49. Other short opinions/comments on moderate/low cancer genetic risk markers in medical practice and the article Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology by Lubinski et al., **Breast Cancer Res Treat** 2008 Apr 15. Allan Spigelman. **Hereditary Cancer in Clinical Practice** 2008; 6(2) pp. 67-68.
 50. Harris MF, Pascoe SW, Crossland LJ, Beilby JJ, Veitch C, Spigelman AD. Referral pathways in colorectal cancer: findings from a qualitative study in general practice. **Med J Aust** 2011; 195(4):178 http://www.mja.com.au/public/issues/val/Documents/har11417let_fm.html
 51. Concurrent melanoma and thyroid malignancy in a young woman. Is it genetic? Stewart TJ, Bova R, Spigelman A, Rosen R. **Australian Journal of Dermatology** 2017; 58 (4): 318-319.

REVIEWS

1. General Surgery. Spigelman AD. **Medical Review** 1994; 1 (1): 16.
2. General Surgery. Spigelman AD. **Medical Review** 1995; 1 (2): 20.
3. General Surgery. Spigelman AD. **Medical Review** 1995; 1 (3): 20.
4. General Surgery. Goldberg A, Spigelman AD. **Medical Review** 1995; 1 (4): 19-20.
5. General Surgery. Spigelman AD. **Medical Review** 1996; 2 (2): 16.
6. General Surgery. Spigelman AD. **Medical Review** 1996; 2 (3): 18.
7. General Surgery. Spigelman AD. **Medical Review** 1996; 2 (4): 19.

SERIES EDITED

1. Short Stay Surgery. **Hospital Update**: 1993.

ABSTRACTS

1. Foregut screening in familial adenomatous polyposis (FAP). Spigelman AD, Phillips RKS, Williams CB, Bussey HJR. **Gut** 1988; 29: A1445.
2. Gastro-duodenal adenomas in polyposis – is bile the missing link? Spigelman AD, Williams CB, Granowska M, Phillips RKS. **Gut** 1989; 30: A710-11.
3. Ornithine decarboxylase activity in the upper gastro-intestinal tract in familial adenomatous polyposis. Alstead EM, Brito FCG, Spigelman AD, Phillips RKS, Clark ML, Farthing MJG. **Clinical Science** 1989; 77 (21): 25.
4. Peroperative enteroscopy in Peutz-Jeghers polyposis. Phillips RKS, Spigelman AD, Thomson JPS. **Gut** 1989; 30: A1464.
5. Desmoid tumours and viruses. Spigelman AD, Argent S, Wells C, Crofton-Sleigh C, Venitt S, Phillip RKS. **Int J Colorect Dis** 1990; 5: 53.
6. Gastro-duodenal adenomas in polyposis – is bile the missing link? Spigelman AD, Williams CB, Crofton-Sleigh C, Venitt S, Granowska M, Phillips RKS. **Int J Colorect Dis** 1990; 5: 54.
7. Selected Summaries: Look at the duodenum in familial polyposis. Spigelman AD, Talbot IC, Williams CB, et al. Reviewed by Likier HM, Kurtz C. **Gastroenterology** 1990; 98: 1092-1093.
8. Evaluation of ornithine decarboxylase (ODC) activity as a marker for premalignancy in the stomach and duodenum. Alstead EM, Brito FCG, Spigelman AD, Phillips RKS, Clark ML, Farthing MJG. **Gastroenterology**

- 1990; 98: A269.
9. DNA adducts in the foregut of patients with familial adenomatous polyposis. Spigelman AD, Phillips RKS, Scates DK, Venitt S. In: **Abstracts of the World Congresses of Gastroenterology**. Sydney 1990. Abingdon: The Medicine Group (UK) Ltd 1990: FP 592.
 10. Bile reflux and gastric adenomas in patients with familial adenomatous polyposis. Spigelman AD, Granowska M, Phillips RKS. In: **Abstracts of the World Congresses of Gastroenterology**. Sydney 1990. Abingdon: The Medicine Group (UK) Ltd 1990: FP 595.
 11. Rectal polyposis severity – a guide to duodenal polyposis severity in familial adenomatous polyposis? Spigelman AD, Williams CB, Phillips RKS. In: **Abstracts of the World Congresses of Gastroenterology**. Sydney 1990. Abingdon: The Medicine Group (UK) Ltd 1990: PP 203.
 12. Bile reflux and gastric adenomas in patients with familial adenomatous polyposis (FAP). Spigelman AD, Granowska M, Phillips RKS. **Gut** 1990; 31: A1202-3.
 13. Excess of DNA-adducts in the foregut of patients with familial adenomatous polyposis. Spigelman AD, Scates DK, Venitt S, Williams CB, Phillips RKS. **Gut** 1990; 31: A1200.
 14. Detection by ³²P-Postlabelling of DNA adducts in the upper gastrointestinal tract of patients with familial adenomatous polyposis. Spigelman AD, Phillips RKS, Scates DK, Venitt S. **Br J Cancer** 1990; 62: 541.
 15. Relationship between rectal and duodenal polyposis in familial adenomatous polyposis. Spigelman AD, Williams CB, Phillips RKS. **Br J Surg** 1990; 77: 1421.
 16. Significant excess of DNA-adducts in the foregut of patients with familial adenomatous polyposis. Spigelman AD, Scates DK, Venitt S, Phillips RKS. **Br J Surg** 1991; 78: 758.
 17. Bile and DNA damage in an animal model. Spigelman AD, Scates DK, Venitt S, Phillips RKS. **Gut** 1991; 32: A1240.
 18. Acetylator status: link between hepatic metabolism and colorectal cancer. Farmer KCR, Oliver SE, Spigelman AD, Bennett PN, Phillips RKS. **Gut** 1991; 32: A1255.
 19. Gastric and duodenal polyps in familial adenomatous polyposis. Talbot IC, Domizio P, Spigelman AD, Williams CB, Phillips RKS. **Int J Colorect Dis** 1991; 6: 232-3.
 20. Bile and familial adenomatous polyposis: an update. Spigelman AD, Williams CB, Venitt S, Crofton-Sleigh C, Scates DK, Owen RW, Hill MJ, Granowska M, Talbot IC, Farmer CK, Phillips RKS. **Int J Colorect Dis** 1991; 6: 233.
 21. Evidence at the DNA-base level for the presence of carcinogens in the foregut of patients with familial adenomatous polyposis (FAP). Venitt S, Spigelman AD, Scates DK, Phillips RKS. **Int J Colorect Dis** 1991; 6: 233.
 22. Prospective placebo controlled double blind trial of sulindac in the management of upper gastrointestinal polyps in familial adenomatous polyposis (FAP). Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. **Int J Colorect Dis** 1991; 6: 233-4.
 23. Assessment of pharmacogenetic polymorphisms in familial adenomatous polyposis. Farmer KCR, Spigelman AD, Phillips RKS, Lledo P, Abrams SML. **Int J Colorect Dis** 1991; 6: 235.
 24. Significant excess of DNA-adducts in the foregut of patients with familial adenomatous polyposis (FAP). Spigelman AD, Scates DK, Venitt S, Phillips RKS. **Eur J Surg Res** 1991; 23 (Suppl 1): 6.
 25. DNA adducts in the gut of rats given bile from patients with familial adenomatous polyposis and controls. Scates DK, Venitt S, Spigelman AD, Phillips RKS. **Mutagenesis** 1991; 6(5): 438.
 26. Acetylation status in familial polyposis and colorectal carcinoma. Oliver SE, Farmer KC, Spigelman AD, Phillips RKS, Bennett PN, Notarianni LJ. **Br J Clin Pharm** 1991; 32(5): 650P.
 27. Duodenal polyp progression: a longitudinal study in patients with familial adenomatous polyposis (FAP). Nugent KP, Spigelman AD, Williams CB, Phillips RKS. **Gut** 1992; 33 (Supplement No 1): S73.
 28. Carcinogens in bile: results of a bioassay. Spigelman AD, Scates DK, Venitt S, Phillips RKS. **Br J Surg** 1992; 79: 452.
 29. ³²P-Postlabelling studies on the in vitro genotoxicity of bile from patients with familial adenomatous polyposis and controls. Scates DK, Spigelman AD, Phillips RKS, Radley S, Neoptolemos JP, Venitt S. **Mutagenesis** 1992; 7: 365.
 30. Acetylator status: a link between hepatic metabolism and colorectal cancer. Farmer KCR, Oliver SE, Spigelman AD, Bennett PN, Phillips RKS. **Dis Colon Rectum** 1992; 35(5): P41-2.
 31. Abnormal P4501A2 activity in patients with familial adenomatous polyposis. Spigelman AD, Oliver SE, Farmer KCR, Notarianni LJ, Bennett PN, Phillips RKS. **Br J Surg** 1992; 79: 1230.
 32. Randomised controlled clinical trial of Sulindac on intestinal polyposis in patients with FAP. Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. **Gut** 1992; 33 (Supplement No 2): S33.

33. A prospective randomized double-blind placebo-controlled trial of sulindac in the management of gastrointestinal polyps in familial adenomatous polyposis (FAP). Farmer KCR, Nugent KP, Spigelman AD, Williams CB, Phillips RKS. **Journal of Gastroenterology and Hepatology** 1992; 7: A32.
34. Pouches in patients with familial adenomatous polyposis are not at increased risk for neoplasia. Nugent KP, Spigelman AD, Nicholls RJ, Talbot IC, Phillips RKS. **Br J Surg** 1993; 80: 661.
35. Analysis of deaths in familial adenomatous polyposis treated by colectomy and ileorectal anastomosis. Nugent KP, Spigelman AD, Phillips RKS. **Br J Surg** 1993; 80: 662.
36. Sulindac and intestinal polyps: a randomised controlled trial. Spigelman AD, Nugent KP, Farmer KCR, Williams CB, Phillips RKS. **Cancer Det Prev** 1993; 17(1): 191.
37. Carcinogen metabolism and DNA adducts in patients at high risk for intestinal cancer and in controls. Spigelman AD, Venitt S, Scates DK, Nugent KP, Penna C, Foulds S, Bennett PN, Phillips RKS. **Cancer Det Prev** 1993; 17(1): 231.
38. Bile and DNA adducts – an in-vitro genotoxicity study. Spigelman AD, Scates DK, Venitt S, Nugent KP, Phillips RKS. **Gut** 1993; 34: S7.
39. Outcome of duodenotomy for duodenal polyposis in patients with familial adenomatous polyposis. Spigelman AD, Penna C, Nugent KP, Phillips RKS. **Gut** 1993; 34: S20.
40. P4501A2 activity in patients with colorectal cancer and familial polyposis (FAP) and their at risk relatives. Notarianni LJ, Oliver S, Bennett PN, Farmer KC, Spigelman AD, Phillips RKS. **Br J Clin Pharm** 1994; 35: .
41. Pouches in patients with familial adenomatous polyposis (FAP) are not at increased risk for neoplasia. Nugent KP, Spigelman AD, Nicholls RJ, Talbot IC, Neale K, Phillips RKS. **Int J Colorect Dis** 1994; 9: 52.
42. Duodenal polyp follow up in FAP. Spigelman AD, Nugent KP, Williams CB, Phillips RKS. **Int J Colorect Dis** 1994; 9: 53.
43. The role of duodenotomy in the treatment of duodenal polyposis. Spigelman AD, Penna C, Nugent KP, Tired E, Phillips RKS. **Int J Colorect Dis** 1994; 9: 53.
44. Further evidence that FAP bile contains an excess of DNA damaging agents. Venitt S, Spigelman AD, Scates DK, Nugent KP, Phillips RKS. **Int J Colorect Dis** 1994; 9: 54.
45. Assessment of hepatic metabolism of carcinogens in FAP and control patients. Spigelman AD, Nugent KP, Bennett PN, Penna C, Foulds S, Phillips RKS. **Int J Colorect Dis** 1994; 9: 54.
46. Coexisting adenomas and periampullary cancer in FAP patients. Talbot IC, Penna C, Nugent KP, Phillips RKS, Spigelman AD. **Int J Colorect Dis** 1994; 9: 54.
47. Randomized controlled trial of Sulindac on intestinal polyposis in FAP. Nugent KP, Farmer KCR, Spigelman AD, Williams CB, Phillips RKS. **Int J Colorect Dis** 1994; 9: 56.
48. p53 overexpression is closely correlated with grade of duodenal neoplasms in familial adenomatous polyposis (FAP). Kashiwagi H, Spigelman AD, Talbot IC, Phillips RKS. **Gut** 1994; 35 (Supplement No 5): S39.
49. Germline APC mutation at codon 1061 is associated with severe duodenal polyposis but not high colonic polyp counts in familial adenomatous polyposis (FAP). Debinski HS, Pack K, Cottrell S, Hodgson SV, Spigelman A, Phillips RKS. **Gut** 1994; 35 (Supplement No 5): S40.
50. GST Mu1 genetic polymorphism in familial adenomatous polyposis (FAP). Debinski HS, Cottrell S, Phillips RKS, Spigelman AD. **Gut** 1994; 35 (Supplement No 5): S63.
51. The relation between germline APC mutations at codon 1309 and severity of duodenal polyposis in familial adenomatous polyposis (FAP). Debinski HS, Cottrell S, Hodgson SV, Spigelman A, Phillips RKS. **Journal of Gastroenterology and Hepatology** 1994; 9 (5): A103.
52. GST Mu1 genetic polymorphism in familial adenomatous polyposis (FAP). Debinski HS, Cottrell S, Phillips RKS, Spigelman AD. **Journal of Gastroenterology and Hepatology** 1994; 9 (5): A99.
53. Progression of duodenal polyps in familial adenomatous polyposis (FAP). Debinski HS, Nugent KP, Williams CB, Talbot IC, Phillips RKS, Spigelman AD. **Journal of Gastroenterology and Hepatology** 1994; 9 (5): A109.
54. Might antacids reduce duodenal polyposis in patients with familial adenomatous polyposis? Scates DK, Venitt S, Phillips RKS, Spigelman AD. **Br J Surg** 1995; 82: 701.
55. Liposome mediated delivery of the adenomatous polyposis coli gene into a colonic cancer cell line. Hargest R, Williamson R (Spigelman AD). **Br J Surg** 1995; 82: 691.
56. DNA ploidy studies of sporadic colorectal polyps. Tahir-Kheli ND, Sarker SK, Levine TS, Spigelman AD, Coleman DV. **J Path** 1995; 175: Suppl. 119^A.
57. p53 alteration occurs more frequently than ras mutation in duodenal adenomas in familial adenomatous polyposis. Kashiwagi H, Spigelman AD, Desai D, Debinski HS, Talbot IC, Phillips RKS. **J Path** 1995; 175: Suppl. 120^A.

58. Colorectal polyp density equates with cancer risk in Familial Adenomatous Polyposis. Debinski HS, Neale K, Love S, Phillips RKS, Spigelman AD. **Dis Colon & Rectum** 1995; 38: P40.
59. Photodynamic therapy for the endoscopic treatment of polyps in familial adenomatous polyposis. Mlkvy P, Messman H, Ng TM, Pauer M, Regula J, Conio M, Debinski H, Spigelman A, Phillips R, Bown SG. **Gut** 1995; 36 (Suppl 1): A39.
60. Colorectal polyp density equates with cancer risk in familial adenomatous polyposis. Debinski HS, Neale K, Spigelman A, Phillips RKS. **Gastroenterology** 1995; 108: A458.
61. Endoscopic ultrasound (EUS) – a new tool for assessment of the foregut in FAP patients. Debinski HS, Muller A, Spigelman AD, Hatfield A, Phillips RKS. **Gastroenterology** 1995; 108: A459.
62. Genotype-phenotype correlation in familial adenomatous polyposis (FAP). Debinski HS, Pack K, Hodgson S, Cottrell S, Neale K, Spigelman AD, Phillips RKS. **Gastroenterology** 1995; 108: A459.
63. GST Mu1 genetic polymorphism in familial adenomatous polyposis (FAP). Debinski HS, Cottrell S, Phillips RKS, Spigelman AD. **Gastroenterology** 1995; 108: A459.
64. A prospective double-blind placebo controlled study of the management of duodenal and rectal polyps in familial adenomatous polyposis with low dose aspirin, using several measures of outcome. Debinski HS, Desai D, Spigelman AD, Phillips RKS. **Gastroenterology** 1995; 108: A459.
65. Sulindac has maximal effect on small but not large polyps in the duodenum in patients with familial adenomatous polyposis. Debinski HS, Trojan J, Love S, Nugent KP, Spigelman AD, Phillips RKS. **Gastroenterology** 1995; 108:A460.
66. Is the liver implicated in chronic ulcerative colitis associated colon cancer? Debinski HS, Rogers L, Nugent K, Spigelman AD, Phillips RKS. **Gastroenterology** 1995; 108: A807.
67. Regression of small duodenal polyps after sulindac treatment in patients with FAP. Trojan J, Debinski HS, Spigelman AD, Williams CB, Phillips RKS. **Gut** 1995; 37(2): A136.
68. Photodynamic therapy for polyps in familial polyposis – first report. Messman H, Mlkvy P, Debinski H, Regula J, Conio M, MacRobert A, Spigelman A, Phillips R, MacRobert A, Bown S. **Endoscopy** 1995; 27(7):
69. Photodynamic therapy for polyps in familial polyposis – first report. Mlkvy P, Messman H, Debinski H, Regula J, Conio M, MacRobert A, Spigelman A, Phillips R, Bown S. **Int J Colorectal Dis** 1996; 11: 103.
70. Might antacids reduce duodenal polyposis in patients with familial adenomatous polyposis? Scates DK, Venitt S, Phillips RKS, Spigelman AD. **Int J Colorectal Dis** 1996; 11: 104.
71. Colorectal polyp density equates with cancer risk in familial adenomatous polyposis (FAP). Debinski HS, Neale K, Love S, Spigelman AD, Phillips RKS. **Int J Colorectal Dis** 1996; 11: 105-106.
72. Genotype-phenotype correlation in FAP. Debinski HS, Pack K, Love S, Neale K, Cottrell S, Hodgson SV, Williams CB, Spigelman AD, Phillips RKS. **Int J Colorectal Dis** 1996; 11: 106.
73. Prostaglandins – their role in carcinogenesis. Nugent KP, Spigelman AD, Phillips RKS. **Int J Colorectal Dis** 1996; 11: 109.
74. GST Mu1 genetic polymorphism in familial adenomatous polyposis (FAP). Debinski HS, Cottrell S, Phillips RKS, Spigelman AD. **Int J Colorectal Dis** 1996; 11: 107-108.
75. p53 overexpression is a hallmark of duodenal adenomas in familial adenomatous polyposis. Kashiwagi H, Spigelman AD, Debinski HS, Neale K, Talbot IC, Phillips RKS. **Int J Colorectal Dis** 1996; 11: 108.
76. Bile from transgenic mice carrying a mutation in the *Apc* gene induces more DNA damage than does bile from wild-type mice from the same genetic background. Scates DK, Venitt S, Spigelman AD, Phillips RKS, Mathers JC, Fodde R. **Gut** 1996; 38 (suppl 1): A18.
77. Familial adenomatous polyposis: the risk of extracolonic cancer. Nugent KP, Spigelman AD, Phillips RKS. **Int J Colorectal Disease** 1996; 11: 132.
78. Studies of the nature and origin of DNA adducts formed by bile from patients with familial adenomatous polyposis and from normal patients. Venitt S, Scates DK, Spigelman AD, Phillips RKS **Int J Colorectal Disease** 1997; 12: 344-366.
79. Bile from transgenic mice carrying a mutation in the *Apc* gene induces more DNA damage than does bile from wild-type mice from the same genetic background. Scates DK, Venitt S, Spigelman AD, Phillips RKS, Mathers JC, Fodde R. **Int J Colorectal Disease** 1997; 12: 344-366.
80. Genetic Testing in Australia. Spigelman AD. **ANZ J Surg** 1998; 68 (Suppl): A50.
81. Disease expression in a large Peutz-Jeghers syndrome family. Scott RJ, Mowat D, Spigelman AD, Phillips MM. **J Gastroenterol. Hepatol.** 1999; 14 (Suppl.): A66.
82. Relative infrequency of *Helicobacter Pylori* in the stomach of patients with FAP. Wallace MH, Forbes A, Spigelman AD, Phillips RKS. **J Gastroenterol. Hepatol.** 1999; 14 (Suppl.): A68.
83. DNA adduct profiles in the duodenum of patients with FAP given antacids compared to controls. Wallace MH,

- Forbes A, Spigelman A, Hewer A, Venitt S, Phillips RKS. **J Gastroenterol. Hepatol.** 1999; 14 (Suppl.): A69.
84. Relaunch of a register for hereditary bowel cancer. French JA, Spigelman AD, Armstrong BA. **J Gastroenterol. Hepatol.** 1999; 14 (Suppl.): A84.
85. Establishment of a regional family cancer service. Spigelman AD, Turner G, Scott RJ, Meldrum C, Davidson P, Burgess B, Groombridge C, Hammond A. **J Gastroenterol. Hepatol.** 1999; 14 (Suppl.): A84.
86. *In-vitro* inhibition of proliferation of a prostate cancer cell line by Indole-3-carbinol, a component of cruciferous vegetables. Spigelman AD, Frydoon far H. **Aust NZ J Surg** 2000; 70 (Suppl.): A75-76.
87. *In-vitro* inhibition of proliferation of a colon cancer cell line by Indole-3-carbinol, a component of cruciferous vegetables: mechanism for chemoprevention? Spigelman AD, Frydoon far H. **ANZ J Surg** 2000; 70 (Suppl.): A64-65.
88. An audit of open and laparoscopic inguinal hernia repair. Spigelman AD, Eno LM. **ANZ J Surg** 2000; 70 (Suppl.): A80.
89. National Audit of Colorectal Cancer Care Management: - Why & How. Spigelman AD, Anderson S. **ANZ J Surg** 2000; 70 (Suppl.): A56-57.
90. Patient safety: development of a framework for analysing adverse events. Spigelman AD, Swan JR. **ANZ J Surg** 2000; 70 (Suppl.): A102-103.
91. Medical record retention – what do clinicians think? Spigelman AD. **ANZ J Surg** 2000; 70 (Suppl.): A100-101.
92. A Survey of Surgical Audit in Australia. Spigelman AD, Eno LM. **ANZ J Surg** 2000; 70 (Suppl.): A82.
93. Establishment of a Regional Familial Colorectal Cancer Service. Spigelman AD. **ANZ J Surg** 2000; 70 (Suppl.): A64.
94. Adverse events in 9 common elective surgical procedures. Kable AK, Gibberd RW, Spigelman AD. **ANZ J Surg** 2000; 70 (Suppl.): A78.
95. Surgical Adverse Events in Australia. Kable AK, Gibberd RW, Spigelman AD. **ANZ J Surg** 2000; 70 (Suppl.): A77.
96. Duodenal Cancer in Familial Adenomatous Polyposis. Groves CJ, Saunders BP, Spigelman AD, Phillips RKS. **Gut** 2001; 48 (Suppl 1): A3.
97. *In-vitro* inhibition of proliferation of a colon cancer cell line by Sulforaphane, a component of cruciferous vegetables: mechanism for chemoprevention? Frydoon H, Spigelman AD. **ANZ J Surg** 2001; 71 (Suppl.): A23.
98. The National Colorectal Cancer Care Survey – Progress Report. Anderson SE, Spigelman AD. **ANZ J Surg** 2001; 71 (Suppl.): A32.
99. Familial Colorectal Cancer: changing the system. Spigelman AD, Scott RJ, Burgess B, Groombridge C, Hammond A. **ANZ J Surg** 2001; 71: A117.
100. *In-vitro* inhibition of proliferation of a colon cancer cell line by Indole-3-carbinol, a component of cruciferous vegetables. Frydoon H, Spigelman AD. **ANZ J Surg** 2001; 71: A118.
101. Development of a Clinical Governance model. Spigelman AD. **ANZ J Surg** 2002; 72 (Suppl): A1-3.
102. The Management of Colorectal Cancer in Australia. McGrath DR, Spigelman AD, Anderson SE. **ANZ J Surg** 2002; 72 (Suppl): A19-26.
103. Clinical Governance in Australia. Spigelman AD. **Australian Infection Control** 2002; 7 (2): Abstracts, 6.
104. The Management of Colorectal Cancer in Australia. McGrath D, Anderson S, Spigelman A. **Dis Colon Rectum** 2002; 45 (12): A2.
105. Management of Colorectal Cancer in Australia. McGrath DR, Anderson S, Spigelman AD. **ANZ J Surg** 2003; 73: A5.
106. The Inappropriate Usage of Adjuvant Therapy for Patients with Colorectal Cancer. DR McGrath and AD Spigelman. **ANZ J Surg** 2003; 73: (Suppl.) A20.
107. Surgeon Volume Impacts on Management of Patients with Colorectal Cancer. DR McGrath and AD Spigelman. **ANZ J Surg** 2003; 73: (Suppl.) A21.
108. Appropriateness of Surgery for Patients with Symptomatic Gallstones. DR McGrath, RW Gibberd and AD Spigelman. **ANZ J Surg** 2003; 73: (Suppl.) A38.
109. What Happens to Patients after Discharge? AD Spigelman, R Gibberd and A Kable. **ANZ J Surg** 2003; 73: (Suppl.) A42.
110. A Review of the Australian Incident Monitoring System. AD Spigelman and JR Swan. **ANZ J Surg** 2003; 73: (Suppl.) A73.
111. A Method for Measuring Surgical Audit and Peer Review. AD Spigelman and JR Swan. **ANZ J Surg** 2003; 73: (Suppl.) A74.
112. Skin Antiseptics and Operating Theatre Fires. AD Spigelman and JR Swan. **ANZ J Surg** 2003; 73: (Suppl.) A75.

113. A Comparison of Concordance with NHMRC Guidelines for Patients treated with Colorectal Cancer in Capital Cities and Elsewhere. DR McGrath and AD Spigelman. **ANZ J Surg** 2003; 73: (Suppl.) A97.
114. Attenuated Familial Adenomatous Polyposis (AFAP). Lyster Knudsen A, Tomlinson I, AFAP Study Group: Aretz S, et al, Spigelman A. **Familial Cancer** 2003; 2 (Suppl. 1): 46.
115. Factors influencing the dissemination of genetic information in families with an inherited predisposition to colorectal cancer. Groombridge C, Ingrey A, Gleeson M, Spigelman A, Dudding T. **Familial Cancer** 2003; 2 (Suppl. 1): 69.
116. Advanced duodenal polyposis: Literature Review and experience with pancreas-sparing duodenectomy in patients with Familial Adenomatous Polyposis. Spigelman AD, Gani J, Burgess B, Groombridge C, Dudding T, Ingrey A, Gleeson M, Scott RJ. **Familial Cancer** 2003; 2 (Suppl. 1): 84.
117. Appropriateness of surgery for patients with symptomatic gallstones. McGrath DR, Gibberd RW, Spigelman AD. **Journal of Gastroenterology and Hepatology** 2003; 18 (Suppl.) B2.
118. The inappropriate use of adjuvant therapy for patients with colorectal cancer. McGrath DR, Spigelman AD. **Journal of Gastroenterology and Hepatology** 2003; 18 (Suppl.) B41.
119. The inappropriate use of adjuvant therapy for patients with colorectal cancer in Australia. McGrath DR, Spigelman AD. **EJSO** 2003; 29(9): 789.
120. Surgeon Volume Impacts on Management of Patients with Colorectal Cancer in Australia. DR McGrath and AD Spigelman. **EJSO** 2003; 29(9): 789.
121. Experience with a policy for the introduction of new interventional procedures. AD Spigelman. **ANZ J Surg** 2004; 74: (Suppl.) A83.
122. The impact of age on the treatment of colorectal cancer in Australia. McGrath DR, Spigelman AD. **Ann R Coll Surg Engl** 2004; 86: 228.
123. The role of the MLH1 germline epimutation in the development of colorectal cancer. Hitchins M et al, Spigelman A, et al Ward R. **Familial Cancer** 2005; 4 (Suppl. 1): 43.
124. Informing at-risk relatives in New South Wales families with hereditary bowel cancer syndromes: evaluation. Groombridge C, Burgess B, Sitas F, Spigelman A, Weir L. **Familial Cancer** 2005; 4 (Suppl. 1): 47 – 48.
125. Prevalence of germline mutations, Y165C and G382D of the *MYH* gene in patients with colorectal adenomatous polyps. Scott RJ, Kairupan C, Meldrum CJ, Ashton K, Milward L, Spigelman AD, Kirk J, Tucker K, Ward R. **Familial Cancer** 2005; 4 (Suppl. 1): 125 - 126.
126. CAPP2: a trial of aspirin and/or resistant starch in people at risk of hereditary non-polyposis colorectal cancer (HNPCC). Macrae FA, Ives PC, Winship I, Boussioutas A, Legget BA, Scott RJ, Spigelman A, Walpole I, Goldblatt J, Burn J. **Hereditary Cancer in Clinical Practice** 2005; 3(4) (Suppl. 1): S18.
127. Results of an intervention to improve compliance with prophylactic antibiotic protocols for elective surgery. Spigelman AD, Kable AK, Gibberd RW. **ANZ J Surg** 2006; (Suppl. 1): A28.
128. Preventing litigation: the role of clinical governance. Spigelman AD. **ANZ J Surg** 2006: (Suppl. 1): A42.
129. Your InSiGHT Membership. Neale K, Spigelman A. **Familial Cancer** 2013; 12 (Suppl. 2): S54.
130. The importance of a large sample cohort for studies on modifier genes influencing disease development in FAP patients. Talseth-Palmer BA, et al, Spigelman A, et al. **Familial Cancer** 2013; 12 (Suppl. 2): S56.
131. Revealing cancer complexity – identification of Lynch syndrome cases. Talseth-Palmer BA, et al, Spigelman A, et al. **Familial Cancer** 2013; 12 (Suppl. 2): S73.
132. Metachronous central nervous system desmoids tumours and thyroid carcinoma in a young familial adenomatous patients. Butel-Simoes G, Spigelman A. **Familial Cancer** 2013; 12 (Suppl. 2): S79.
133. Analysis of patient reports on the referral process in two cancer genetic services. Butel-Simoes, Spigelman A. **Familial Cancer** 2013; 12 (Suppl. 2): S80.
134. Lynch syndrome expert opinion questionnaire - what would you do? Schneider R et al Spigelman A et al. **Familial Cancer** 2013; 12 (Suppl. 2): S104.
135. Targeted next-generation sequencing - Identification of Lynch syndrome cases. Talseth-Palmer BA, Evans TJ, Spigelman A, Scott RJ. **European Journal of Cancer** 2014; 50: S103.
136. The curious case of a woman with two BRCA1 mutations in trans. Scott RJ et al. Spigelman AD. **Hereditary Cancer in Clinical Practice** 2015: 13 (Suppl 2): A11.
137. Treatment of desmoid disease in a 51-year-old male with Familial Adenomatous Polyposis (FAP). Danos I, Lynagh L, Spigelman AD. **Familial Cancer** 2017; 16 (Suppl): S107.
138. Novel duplication of SCG5/GREM1 as a cause for hereditary mixed polyposis syndrome (HMPS). Lynagh L, Danos I, Spigelman AD. **Familial Cancer** 2017; 16 (Suppl): S108-109.
139. A potential chemopreventative food for familial adenomatous polyposis: the ausfap study. Macrae F,

- Boussioutas A, Flanders B, Spigelman A. et al. . **Familial Cancer** 2017; 16 (Suppl): S85.
140. Adherence to guidelines for the referral of patients with colorectal cancer and abnormal immunohistochemistry tumour tissue testing for assessment for Lynch syndrome. Han J, Spigelman AD. **Familial Cancer** 2019; 18 (Suppl): S36-37.
 141. A pathway to facilitate referral of patients with abnormal tumour mismatch repair immunohistochemistry to Cancer Genetics. Lynagh L, Danos I, McDonald C, Spigelman A. **Familial Cancer** 2019; 18 (Suppl): S67.
 142. Recruitment to the Cancer Prevention Programme – the New South Wales experience. Lynagh L, Danos I, McDonald C, Khan Z, Macrae F, Kirk J, Toh J, Spigelman A. **Familial Cancer** 2019; 18 (Suppl): S68.
 143. Can Butyrate prevent colon cancer? The AusFAP study. Macrae F et al Spigelman A et al. **Familial Cancer** 2019; 18 (Suppl): S86.

MEETING REPORTS

1. Report of the 4th Biennial Meeting of the Leeds Castle Polyposis Group. Spigelman AD. **European J Cancer Prev** 1991; 1: 75-76.
2. FAP Registry Updates – England. Spigelman AD. **Hereditary Colon Cancer Newsletter** 1991; (2): 5.
3. Report of the 7th Biennial Meeting of the Leeds Castle Polyposis Group. Spigelman AD. **Int J Colorectal Disease** 1997; 12: 344-366.

PRESENTATIONS TO LEARNED SOCIETIES

Oral Presentations:

1. Post-cholecystectomy abdominal pain. Spigelman AD, Thomson JPS, Phillips RKS. *Royal Society of Medicine (Clinical Section)*, London, December 9, 1988 (awarded the Alan Edwards Memorial Prize).
2. Gastro-duodenal adenomas in polyposis – is bile the missing link? Spigelman AD, Williams CB, Granowska M, Phillips RKS. *British Society of Gastroenterology*, Spring Meeting, Bradford, April 13, 1989.
3. Peutz-Jeghers polyps: laissez-faire? Spigelman AD, Williams CB, Phillips RKS. *Royal Society of Medicine (Clinical Section)*, London, April 14, 1989.
4. Desmoid Tumours and viruses. Spigelman AD, Argent S, Wells C, Crofton-Sleigh C, Venitt S, Phillips RKS. *Leeds Castle Polyposis Group* (Third Biennial Meeting), Dormy House, Worcestershire, June 15-17, 1989.
5. Gastro-duodenal adenomas in polyposis – the role of bile. Spigelman AD, Williams CB, Talbot IC, Granowska M, Phillips RKS. *Leeds Castle Polyposis Group* (Third Biennial Meeting), Dormy House, Worcestershire, June 15-17, 1989.
6. Upper gastrointestinal polyps in familial adenomatous polyposis. Spigelman AD, Williams CB, Bussey HJR, Phillips RKS. *Royal Society of Medicine, Tripartite Meeting (Section of Coloproctology and Colorectal Societies of Australasia and of America)*, Birmingham, June 19-21, 1989.
7. Relationship between rectal and duodenal polyposis in familial adenomatous polyposis. Spigelman AD, Williams CB, Phillips RKS. *Surgical Research Society* (72nd meeting), Southampton, July 6, 1990.
8. Detection of DNA adducts in the upper gastrointestinal tract of patients with familial adenomatous polyposis using ³²P-postlabelling. Spigelman AD, Phillips RKS, Scates DK, Venitt S. *European Environmental Mutagenesis Society*, York, UK, July 24, 1990 (Annual Meeting).
9. DNA adducts in the foregut of patients with familial adenomatous polyposis. Spigelman AD, Phillips RKS, Scates DK, Venitt S. *World Congresses of Gastroenterology, Digestive Endoscopy and Colo-Proctology* Sydney, Australia, August 26-30, 1990.
10. Bile reflux and gastric adenomas in patients with familial adenomatous polyposis. Spigelman AD, Granowska M, Phillips RKS. *World Congresses of Gastroenterology, Digestive Endoscopy and Colo-Proctology*, Sydney, Australia, August 26-30, 1990.
11. Bile reflux and gastric adenomas in patients with familial adenomatous polyposis. Spigelman AD, Granowska M, Phillips RKS. *British Society of Gastroenterology*, Autumn Meeting, University of Southampton, September 26-28, 1990.
12. Pathogenesis of foregut tumours in familial adenomatous polyposis. Spigelman AD, Scates DK, Venitt S, Phillips RKS. *Royal Society of Medicine (Section of Coloproctology)*, London, November 28, 1990.
13. Significant excess of DNA-adducts in the foregut of patients with familial adenomatous polyposis. Spigelman AD, Scates DK, Venitt S, Phillips RKS. *Surgical Research Society* (73rd meeting), London, January 1991.
14. Bile and familial adenomatous polyposis: an update. Spigelman AD, Williams CB, Venitt S, Crofton-Sleigh C, Scates DK, Owen RW, Hill MJ, Granowska M, Talbot IC, Farmer CK, Phillips RKS. *Leeds Castle Polyposis Group* (Fourth Biennial Meeting), Fort Lauderdale, Florida, USA, May 9-11, 1991.
15. Carcinogens in bile: results of a bioassay. Spigelman AD, Scates DK, Venitt S, Phillips RKS. *Surgical Research*

- Society* (75th meeting), London, January 1992.
16. Carcinogen metabolism and DNA adducts in patients at high risk for intestinal cancer and in controls. Spigelman AD, Venitt S, Scates DK, Nugent KP, Penna C, Foulds S, Bennett PN, Phillips RKS. *International Society for Preventive Oncology*, Meeting on Cofactor Interactions and Cancer Prevention, Nice, March 17-19, 1993.
 17. Sulindac and intestinal polyps: a randomised controlled trial. Spigelman AD, Nugent KP, Farmer KCR, Williams CB, Phillips RKS. *International Society for Preventive Oncology*, Meeting on Cofactor Interactions and Cancer Prevention, Nice, March 17-19, 1993.
 18. Duodenal polyp follow up in FAP. Spigelman AD, Nugent KP, Williams CB, Phillips RKS. *Leeds Castle Polyposis Group* (Fifth Biennial Meeting), Copenhagen, June 3-5, 1993.
 19. The role of duodenotomy in the treatment of duodenal polyposis. Spigelman AD, Penna C, Nugent KP, Tiret E, Phillips RKS. *Leeds Castle Polyposis Group* (Fifth Biennial Meeting), Copenhagen, June 3-5, 1993.
 20. Assessment of hepatic metabolism of carcinogens in FAP and control patients. Spigelman AD, Nugent KP, Bennett PN, Penna C, Foulds S, Phillips RKS. *Leeds Castle Polyposis Group* (Fifth Biennial Meeting), Copenhagen, June 3-5, 1993.
 21. Intestinal cancer and carcinogen exposure. Spigelman AD. *St. Mark's Association* (27th Annual Meeting), London, June 25, 1993.
 22. Photodynamic therapy for polyps in familial polyposis – first report. *Leeds Castle Polyposis Group* (Sixth Biennial Meeting), Toronto, May 25-27, 1995.
 23. How to harness a hospital IT system to enhance continuity of patient care: a pilot study. *Surgical Audit: where are we now?* *Royal College of Surgeons of England & the Clinical Audit Association*. London, January 25, 1996.
 24. The Relationship between APC Genotype, Polyp Distribution and Oral Sulindac Treatment in the Colon and Rectum of Patients with Familial Adenomatous Polyposis (FAP). Scott RJ, Guldenschuh I, Hurlimann R, Muller A, Ammann R, Mullhaupt B, Dobbie Z, Zala GF, Flury R, Seelentag W, Roth J, Meyenberger C, Fried M, Hoppeler T and Spigelman AD. *Genetics into the New Millenium. 23rd Annual Scientific Meeting of the Human Genetics Society of Australasia and 13th Annual Scientific Meeting of the Australasian Society for Inborn Errors of Metabolism*. 30 August – 2 September 1999, EventSite, Australian Technology Park, Sydney, Australia.
 25. *In-vitro* inhibition of proliferation of a prostate cancer cell line by Indole-3-carbinol, a component of cruciferous vegetables. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Melbourne, May 7-12, 2000.
 26. An audit of open and laparoscopic inguinal hernia repair. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Melbourne, May 7-12, 2000.
 27. National audit of colorectal cancer care management: - Why & How. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Melbourne, May 7-12, 2000.
 28. Patient safety: development of a framework for analysing adverse events. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Melbourne May 7-12, 2000.
 29. Medical record retention – what do clinicians think? *Annual Scientific Congress, Royal Australasian College of Surgeons*, Melbourne, May 7-12, 2000.
 30. Familial Colorectal Cancer: Changing the System. *Annual Scientific Meeting, Surgical Research Society of Australasia*, Adelaide, August 10, 2000.
 31. *In-vitro* inhibition of proliferation of a colon cancer cell line by Indole-3-carbinol, a component of cruciferous vegetables. Frydoon far H, Spigelman AD. *Annual Scientific Meeting, Surgical Research Society of Australasia*, Adelaide, August 11, 2000.
 32. Genetic discrimination experienced by Australian families affected by hereditary bowel cancer. *3rd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer*, Venice, April 26-28, 2001.
 33. Familial Colorectal cancer: Improving the System. *3rd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer*, Venice, April 26-28, 2001.
 34. *In-vitro* inhibition of proliferation of a colon cancer cell line by Sulforaphane, a component of cruciferous vegetables. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Canberra, May 6-11, 2001.
 35. Implementing Clinical Governance. Opening Plenary Session, *Annual Scientific Congress, Royal Australasian College of Surgeons*, Adelaide, May 11, 2002.
 36. Clinical Governance in Australia. *Australian Infection Control Association Second Biennial Conference*, Brisbane, June 7, 2002.
 37. The National Colorectal Cancer Care Survey - Results. *Clinical Oncological Society of Australia Annual Scientific Meeting*. Sydney, November 28, 2002.

38. What happens to Patients after Discharge? *Annual Scientific Congress, Royal Australasian College of Surgeons*, Brisbane, May 8, 2003.
39. A Review of the Australian Incident Monitoring System. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Brisbane, May 7, 2003.
40. A Method for Measuring Surgical Audit and Peer Review. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Brisbane, May 7, 2003.
41. Skin Antiseptics and Operating Theatre Fires. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Brisbane, May 8, 2003.
42. Measuring Clinical Audit and Peer Review Practice - the Hunter Health Experience. *Institute for International Research (IIR) 3rd Annual Adverse Events Conference*, Melbourne, July 29, 2003.
43. National Patterns of Care for Colorectal Cancer. *Combined Australasian Colorectal Scientific Meeting*, Sydney, September 19-20, 2003.
44. Colorectal Cancer Patterns of Care. *Hunter Surgical Society Meeting*, Nelson Bay, November 2, 2003.
45. Experience with a policy for the introduction of new interventional procedures. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Melbourne, May 4, 2004.
46. Preventing litigation: the role of clinical governance. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Sydney, May 15, 2006.
47. Results of an intervention to improve compliance with prophylactic antibiotic protocols for elective surgery. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Sydney, May 18, 2006.
48. Clinical Governance; a potpourri of experience from NSW. *6th Annual Institute for International Research (IIR) Adverse Event Management Congress*, Melbourne, June 14, 2006.
49. Hypothetical: Patient Safety Challenges from the Shop Floor through to Head Office. *Clinical Governance Australia 2006, Institute for International Research (IIR), Conference*, Sydney, October 16, 2006.
50. Discussion Panel Moderator: Walking the Talk – Integrated Governance in Australian Healthcare. *Clinical Governance Australia 2006, Institute for International Research (IIR), Conference*, Sydney, October 17, 2006.

Posters:

1. Cystic pancreatic endocrine tumours. Spigelman AD, Ham JM. *First World Congress of Hepato-Pancreatico-Biliary Surgery*, Lund, Sweden, June 9-13, 1986.
2. Bile acid profiles in familial adenomatous polyposis. Spigelman AD, Owen RW, Hill MJ, Phillips RKS. *Royal Society of Medicine, Tripartite Meeting (Section of Coloproctology and Colorectal Societies of Australia and of America)*, Birmingham, June 19-21, 1989.
3. Bile mutagenicity and familial adenomatous polyposis. Spigelman AD, Crofton-Sleigh C, Venitt S, Phillips RKS. *Royal Society of Medicine, Tripartite Meeting (Section of Coloproctology and Colorectal Societies of Australia and of America)*, Birmingham, June 19-21, 1989.
4. The malignant potential of Peutz-Jeghers syndrome. Spigelman AD, Murday V, Phillips RKS. *Royal Society of Medicine, Tripartite Meeting (Section of Coloproctology and Colorectal Societies of Australia and of America)*, Birmingham, June 19-21, 1989.
5. Rectal polyposis severity – a guide to duodenal polyposis severity in familial adenomatous polyposis? Spigelman AD, Williams CB, Phillips RKS. *World Congresses of Gastroenterology, Digestive Endoscopy and Colo-Proctology*, Sydney, Australia, August 26-30, 1990.
6. Carcinogen metabolism and DNA adduct formation in FAP patients and in controls. Spigelman AD, Nugent KP, Scates DK, Penna C, Foulds S, Bennett PN, Venitt S, Phillips RKS. *Tripartite Meeting (Section of Coloproctology and Colorectal Societies of Australasia and of America)*, Sydney, Australia, October 17-20, 1993.
7. The one-stop breast clinic. *First European Forum on Quality Improvement in Health Care*. London, March 9, 1996.
8. Bile from transgenic mice carrying a mutation in the APC gene induces more DNA damage than does bile from wild-type mice from the same genetic background. Scates DK, Venitt S, Spigelman AD, Phillips RKS, Mathers JC, Fodde R. *British Society of Gastroenterology Spring Meeting*, Brighton, March 20-22 1996.
9. Foregut screening in familial adenomatous polyposis (FAP). Spigelman AD, Phillips RKS, Williams CB, Bussey HJR. *British Society of Gastroenterology, Autumn Meeting*, Sheffield, September 14-16, 1988.
10. Upper gastro-intestinal screening in familial adenomatous polyposis (FAP). Spigelman AD, Phillips RKS, Williams CB, Bussey HJR. *Association of Surgeons of Great Britain and Ireland, Annual Meeting*, Edinburgh, March 29-31, 1989.
11. Gallbladder bile acids in familial adenomatous polyposis. Spigelman AD, Owen RW, Hill MJ, Phillips RKS. *Association of Surgeons of Great Britain and Ireland, Annual Meeting*, Edinburgh, March 29-31, 1989.
12. Ornithine decarboxylase activity in premalignant conditions of the upper gastro-intestinal tract. Alstead EM,

- Brito FCG, Spigelman AD, Phillips RKS, Clark ML, Farthing MJG. *Medical Research Society of Great Britain*, Leeds, June 30, 1989.
13. Peroperative enteroscopy in Peutz-Jeghers polyposis Phillips RKS, Spigelman AD, Thomson JPS. *British Society of Gastroenterology*, Autumn Meeting, Dublin, September 27-29, 1989.
 14. Detection by ³²P-Postlabelling of DNA adducts in the upper gastrointestinal tract of patients with familial adenomatous polyposis. Spigelman AD, Phillips RKS, Scates DK, Venitt S. *British Association for Cancer Research* (31st Annual Meeting), University of Sussex, March 20-22, 1990.
 15. Evaluation of ornithine decarboxylase (ODC) activity as a marker for premalignancy in the stomach and duodenum. Alstead EM, Brito FCG Spigelman AD, Phillips RKS, Clark ML, Farthing MJG. *America Gastroenterological Association*, San Antonio, Texas, May 12-18, 1990.
 16. Excess of DNA-adducts in the foregut of patients with familial adenomatous polyposis. Spigelman AD, Scates DK, Venitt S, Williams CB, Phillips RKS. *British Society of Gastroenterology*, Autumn Meeting, University of Southampton, September 26-28, 1990.
 17. Bile and DNA damage in an animal model. Spigelman AD, Scates DK, Venitt S, Phillips RKS. *British Society of Gastroenterology*, Autumn Meeting, University of London, September 25-27, 1991.
 18. Acetylator status: link between hepatic metabolism and colorectal cancer. Farmer KCR, Oliver SE, Spigelman AD, Bennett PN, Phillips RKS. *British Society of Gastroenterology*, Autumn Meeting, University of London, September 25-27, 1991.
 19. Duodenal polyp progression: a longitudinal study in patients with familial adenomatous polyposis (FAP). Nugent KP, Spigelman AD, Williams CB, Phillips RKS. *British Society of Gastroenterology*, Spring Meeting, Sheffield, March 1992.
 20. Adducts, detected by ³²P-postlabelling, in DNA treated in-vitro with bile from patients with familial adenomatous polyposis and from unaffected controls. Scates DK, Spigelman AD, Phillips RKS, Venitt S. *Sixth International Conference on Environmental Mutagens ("ICEM")*, Melbourne, Australia, February 21-26, 1993.
 21. Pouches in patients with familial adenomatous polyposis (FAP) are not at increased risk for neoplasia. Nugent KP, Spigelman AD, Nicholls RJ, Talbot IC, Phillips RKS. *Royal Society of Medicine (Section of Coloproctology)*, London, February 24, 1993.
 22. Bile and DNA adducts – an in-vitro genotoxicity study. Spigelman AD, Scates DK, Venitt S, Nugent KP, Phillips RKS. *British Society of Gastroenterology*, Spring Meeting, University of Manchester, March 1993.
 23. Outcome of duodenotomy for duodenal polyposis in patients with familial adenomatous polyposis. Spigelman AD, Penna C, Nugent KP, Phillips RKS. *British Society of Gastroenterology*, Spring Meeting, University of Manchester, March 1993.
 24. GST Mu1 genetic polymorphism in familial adenomatous polyposis (FAP). Debinski HS, Cottrell S, Phillips RKS, Spigelman AD. *British Society of Gastroenterology*, Annual Meeting, Heriot-Watt University, 21-23 September 1994.
 25. DNA ploidy studies of sporadic colorectal polyps. Tahir-Kheli ND, Sarker SK, Levine TS, Spigelman AD, Coleman DV. *Pathology Society*, 1995.
 26. p53 alteration occurs more frequently than ras mutation in duodenal adenomas in familial adenomatous polyposis. Kashiwagi H, Spigelman AD, Debinski HS, Talbot IC, Phillips RKS. *Pathology Society*, 1995.
 27. Colorectal polyp density equates with cancer risk in familial adenomatous polyposis. Debinski H, Neale K, Love S, Phillips R, Spigelman A. *The American Society of Colon & Rectal Surgeons*, 94th Annual Convention, Montreal, May 7-12, 1995.
 28. "Major" ampullary polyposis progresses more rapidly than does "minor" ampullary polyposis. Kashiwagi H, Spigelman AD, Debinski HS, Talbot IC, Phillips RKS. *Leeds Castle Polyposis Group* (Sixth Biennial Meeting), Toronto, May 25-27, 1995.
 29. Further studies of the role of bile in foregut neoplasia in patients with familial adenomatous polyposis. Venitt S, Scates DK, Phillips RKS, Spigelman AD. *Leeds Castle Polyposis Group* (Sixth Biennial Meeting), Toronto, May 25-27, 1995.
 30. Endoscopic ultrasound (EUS) – a new tool for assessment of the foregut in FAP patients. Debinski H, Muller A, Spigelman AD, Hatfield A, Phillips RKS. *Leeds Castle Polyposis Group* (Sixth Biennial Meeting), Toronto, May 25-27, 1995.
 31. Can we now safely delay prophylactic colectomy in FAP? Spigelman AD, Debinski HS, Neale K, Phillips RKS. *Leeds Castle Polyposis Group* (Sixth Biennial Meeting), Toronto, May 25-27, 1995.
 32. Familial adenomatous polyposis: the risk of extracolonic cancer. Nugent KP, Spigelman AD, Phillips RKS. *Leeds Castle Polyposis Group* (Sixth Biennial Meeting), Toronto, May 25-27, 1995.
 33. A prospective double-blind placebo controlled study of the management of duodenal and rectal polyps in familial adenomatous polyposis with low dose aspirin, using several measures of outcome. Debinski HS, Desai

- D, Spigelman AD, Phillips RKS. *Leeds Castle Polyposis Group* (Sixth Biennial Meeting), Toronto, May 25-27, 1995.
34. Regression of small duodenal polyps after sulindac treatment in patients with FAP. Trojan J, Debinsky HS, Spigelman AD, Williams CB, Phillips RKS. *4th United European Gastroenterology Week*, Berlin, September 17-21, 1995.
 35. How we improved our day care rates. Spigelman AD, Alexander S, Hittinger R. *2nd International Congress on Ambulatory Surgery*, London, 15-18 April, 1997.
 36. Studies of the nature and origin of DNA adducts formed by bile from patients with familial adenomatous polyposis and from normal patients. Venitt S, Scates DK, Spigelman AD, Phillips RKS. *Leeds Castle Polyposis Group* (Seventh Biennial Meeting), The Netherlands, June 6-7, 1997.
 37. Relaunch of a Register for Hereditary Bowel Cancer. French JA, Spigelman AD, Armstrong BA. *2nd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer*, Melbourne and Lorne, Australia. 1 – 6 March 1999.
 38. Establishment of a Regional Family Cancer Service. Spigelman AD, Turner G, Scott RJ, Meldrum C, Davidson P, Burgess B, Groombridge C and Hammond A. *2nd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer*, Melbourne and Lorne, Australia. 1 – 6 March 1999.
 39. APC Gene Testing in patients with Multiple Adenomas of the Colon. Scott RJ, Meldrum C, Crooks R, Groombridge C, Turner G, Spigelman AD, Kirk J, Tucker K and Scott RJ. *Genetics into the New Millenium. 23rd Annual Scientific Meeting of the Human Genetics Society of Australasia and 13th Annual Scientific Meeting of the Australasian Society for Inborn Errors of Metabolism*. 30 August – 2 September 1999, EventSite, Australian Technology Park, Sydney.
 40. Disease Expression in a Large Peutz-Jeghers Syndrome Family. Scott RJ, Mowat D, Spigelman AD, McPhillips M. *Genetics into the New Millenium. 23rd Annual Scientific Meeting of the Human Genetics Society of Australasia and 13th Annual Scientific Meeting of the Australasian Society for Inborn Errors of Metabolism*. EventSite, Australian Technology Park, Sydney, 30 August – 2 September 1999.
 41. *In-vitro* inhibition of proliferation of a prostate cancer cell line by Indole-3-carbinol, a component of cruciferous vegetables. *Urological Society of Australia & Genito-Urinary Oncology Symposium*, Sydney, March 23 – 24, 2000.
 42. A Survey of Surgical Audit in Australia. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Melbourne, May 7-12, 2000.
 43. Establishment of a Regional Familial Colorectal Cancer Service. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Melbourne, May 7-12, 2000.
 44. *In-vitro* inhibition of proliferation of a colon cancer cell line by Indole-3-carbinol, a component of cruciferous vegetables: mechanism for chemoprevention? *Annual Scientific Congress, Royal Australasian College of Surgeons*, Melbourne, May 7-12, 2000.
 45. *In-vitro* study of a GST-mu stimulating agent on a colorectal cancer cell line. *3rd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer*, Venice, April 26-28, 2001.
 46. Genetic heterogeneity and disease diversity in FAP. *3rd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer*, Venice, April 26-28, 2001.
 47. Phenotypic characteristics of HNPCC families sub-divided according to their mutation status. *3rd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer*, Venice, April 26-28, 2001.
 48. The NSW & ACT Hereditary Bowel Cancer Registers: a progress report. *3rd Joint Meeting, Leeds Castle Polyposis Group and International Collaborative Group for Hereditary Non-Polyposis Colorectal Cancer*, Venice, April 26-28, 2001.
 49. The National Colorectal Cancer Care Survey: Progress Report. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Canberra, May 6-11, 2000.
 50. Coordinating a statewide system for informing at-risk relatives in NSW families with hereditary bowel cancer syndromes. *5th Australian Conference on Familial and Genetic Aspects of Cancer*, Barossa Valley, South Australia, July 4-6, 2002.
 51. The Management of Colorectal Cancer in Australia. *Tripartite Colorectal Surgery Meeting, RSM Section of Coloproctology, Colorectal Surgical Society of Great Britain and Colorectal Societies of Australia and of America* Melbourne, October 27-30, 2002.
 52. The post-discharge complication rate in surgical patients and their subsequent management. *19th Conference of*

- International Society for Quality in Healthcare*, Paris, November 5-8, 2002.
53. The Inappropriate Usage of Adjuvant Therapy for Patients with Colorectal Cancer. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Brisbane, May 7, 2003.
 54. Surgeon Volume Impacts on Management of Patients with Colorectal Cancer. *Annual Scientific Congress, Royal Australasian College of Surgeons*, Brisbane, May 7, 2003.
 55. Results of an intervention to improve compliance with prophylactic antibiotic protocols for Elective Surgery. *National Australian Conference on Safety and Quality in Health Care*, Perth, Western Australia, July 14-16, 2003.
 56. The variable effect on proliferation of a colon cancer cell line by the citrus fruit flavonoid Naringenin. *Annual Scientific Meeting, Surgical Research Society*, Melbourne, August 29 – 30, 2003.
 57. Appropriateness of surgery for patients with symptomatic gallstones. DR McGrath, RW Gibberd and AD Spigelman. *Australian Gastroenterology Week*, Cairns, October 7-10, 2003.
 58. The inappropriate usage of adjuvant therapy for patients with colorectal cancer. McGrath DR, Spigelman AD. *UK Association of Surgeons in Training*, Sheffield, February 20-22, 2004.
 59. Surgeon volume impacts on management of patients with colorectal cancer. McGrath DR, Spigelman AD. *UK Association of Surgeons in Training*, Sheffield, February 20-22, 2004.
 60. A multifaceted computer-based intervention to improve smoking cessation in a surgical preadmission clinic. Wolfenden L, Knight J, Campbell E, Spigelman AD, Kerridge R, Moore K. *18th World Conference on Health Promotion & Health Education*, Melbourne, April 26-28, 2004.
 61. Evaluation of the system for informing at-risk relatives in NSW families with hereditary bowel cancer syndromes. Spigelman AD, Weir L, Burgess B, Groombridge C, Overkov A. *Familial Cancer 2004: Research and Practice*, Couran Cove Island Resort, Queensland, August 2004.
 62. Potential mechanisms for the chemoprotective effect of cruciferous vegetables in colorectal cancer: a clinical trial of Indole-3-Carbinol. McGrath D, Frydoonfar H, Spigelman AD. *5th International Symposium on Targeted Anticancer Therapies*, Amsterdam, The Netherlands, March 8-10, 2007.
 63. An updated mutation spectrum in an Australian series of Peutz-Jeghers Syndrome patients provides further evidence for only one gene locus. *2nd Biennial Scientific Meeting of the International Society for Gastrointestinal Hereditary Tumours*. Yokohama, Japan, March 27-30, 2007.
 64. Attenuated Familial Adenomatous Polyposis: Final results from an international collaborative study. *2nd Biennial Scientific Meeting of the International Society for Gastrointestinal Hereditary Tumours*. Yokohama, Japan, March 27-30, 2007.
 65. Case Report: Familial Gastrointestinal Stromal Tumours, oesophageal achalasia, and white forelock in a family with an identified c-kit germ-line mutation. *2nd Biennial Scientific Meeting of the International Society for Gastrointestinal Hereditary Tumours*. Yokohama, Japan, March 27-30, 2007.
 66. Mismatch: MSH2 and MSH6 mutations identified in members of the same family. *2nd Biennial Scientific Meeting of the International Society for Gastrointestinal Hereditary Tumours*. Yokohama, Japan, March 27-30, 2007.
 67. PMS2 and Cancer: the Australasian Experience - abstract at *Familial Cancer 2008: Research and Practice" Conference*, Couran Cove, Australia, August 19-22, 2008.
 68. MTHFR 677 C>T and 1298 A>C polymorphisms and the age of onset of colorectal cancer in hereditary nonpolyposis colorectal cancer. *3rd Biennial Scientific Meeting of the International Society for Gastrointestinal Hereditary Tumours*. Dusseldorf, Germany, July 24-27, 2009.
 69. A qualitative study of referral pathways in colorectal cancer. *National Cancer Research Conference*. Liverpool, November 7-10, 2010.
 70. Your local GP needs a good mate: A qualitative study of referral pathways in colorectal cancer. *Annual Scientific Meeting, Royal Australasian College of Surgeons*, Adelaide, May 2-6, 2011.
 71. Are there champions, experts or competing demands for teaching about patient safety in medical schools? ISQua, Hong Kong, September 2011.
 72. An update on the IMPACT study: Identification of Men with a genetic predisposition to Prostate Cancer: Targeted Screening in BRCA1/2 mutation carriers and controls. *Combined meeting of kConFab, Australian Breast Cancer Family Study, Australasian Colorectal Cancer Family Study, Australian Ovarian Cancer Study, Family Cancer Clinics of Australia and New Zealand & kConFab*, Kingscliff, August 23- 26 2011.
 73. Analysis of Patient Reports on the Referral Process to two Cancer Genetic Services. *The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) 5th Biennial meeting*, 28th – 31st August 2013, Queensland, Australia.
 74. Metachronous central nervous system desmoid tumours and thyroid carcinoma in a young Familial Adenomatous Patient. *The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) 5th*

- Biennial meeting*, 28th – 31st August 2013, Queensland, Australia.
75. Treatment of desmoid disease in a 51-year-old male with Familial Adenomatous Polyposis (FAP). *The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) 7th Biennial meeting*, 5th – 8th July 2017, Florence, Italy.
 76. Novel duplication of SCG5/GREM1 as a cause for hereditary mixed polyposis syndrome (HMPS). *The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) 7th Biennial meeting*, 5th – 8th July 2017, Florence, Italy.
 77. A potential chemopreventative food for Familial Adenomatous Polyposis: The AusFAP Study. *7th International Dietary Fibre Conference*, 4-6 June 2018, Rotterdam, the Netherlands.
 78. ICCOn Familial Cancer Database. *Family Cancer Clinic / kConFab meeting*, Kingscliff September 3-7, 2018.
 79. Adherence to guidelines for the referral of patients with colorectal cancer and abnormal immunohistochemistry tumour tissue testing for assessment for Lynch syndrome *The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) 8th Biennial meeting*, 20-23 March 2019, Auckland, New Zealand.
 80. A pathway to facilitate referral of patients with abnormal tumour mismatch repair immunohistochemistry to Cancer Genetics. *The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) 8th Biennial meeting*, 20-23 March 2019, Auckland, New Zealand.
 81. Recruitment to the Cancer Prevention Programme – the New South Wales experience. *The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) 8th Biennial meeting*, 20-23 March 2019, Auckland, New Zealand.
 82. Can Butyrate prevent colon cancer? The AusFAP study. *The International Society for Gastrointestinal Hereditary Tumours (InSiGHT) 8th Biennial meeting*, 20-23 March 2019, Auckland, New Zealand.
 83. Barriers to pancreatic screening uptake and the utility of PanelPRO as a personalized risk assessment model. Dwarte T, McKay S, Johns A, Ticker K, Spigelman AD, Williams D, Stoita A. *Family Cancer Clinic / kConFab meeting*, August 26-30 2019, Kingscliff, NSW.
 84. Genetic Counselling for individuals at high risk of pancreatic cancer: how can we improve practice? Dwarte T, McKay S, Johns A, Ticker K, Spigelman AD, Williams D, Stoita A. *Family Cancer Clinic / kConFab meeting*, August 26-30 2019, Kingscliff, NSW.

INVITED LECTURES / TALKS

1988

- Upper gastrointestinal neoplasia in familial adenomatous polyposis. *St. Mark's Hospital*, London, April 6, 1988
- What's new in polyposis? Department of Gastroenterology, *St. Bartholomew's Hospital*, London, April 15, 1988
- Peutz-Jeghers syndrome: benign or malignant? *St. Mark's Hospital*, London, July 1, 1988.
- Upper gastrointestinal disease in familial adenomatous polyposis: research at St. Mark's Hospital, London. *Gastroenterology Unit, Prince of Wales Hospital, Sydney*, July 12, 1988.
- Polyps and Polyposis syndromes. *St. Mark's Postgraduate Lecture Course*, London, October 14, 1988 & March 3, 1989
- Polyposis as a model for colorectal cancer – update on clinical and experimental studies. *St. Mark's Hospital*, London, October 28, 1988
- Unusual aspects of familial adenomatous polyposis. *Kings College Hospital*, London, November 23, 1988

1989

- Foregut screening in familial adenomatous polyposis: findings and implications. *Gastroenterology Unit, Whittington Hospital*, London, February 23, 1989
- Foregut disease in polyposis coli – a contradiction in terms. *Department of Gastroenterology and Nutrition, Central Middlesex Hospital*, London, October 13, 1989
- Duodenal polyposis and desmoid tumours. *St. Mark's Hospital Postgraduate Course*, London, October 13, 1989

1990

- Bile and polyps in familial adenomatous polyposis. Combined Gastroenterology meeting, *Royal Prince Alfred Hospital, Sydney*, February 21, 1990
- The foregut in familial adenomatous polyposis. Combined Gastroenterology meeting, *Concord Repatriation Hospital, Sydney*, February 26, 1990
- Polyposis of the foregut. *St. Mark's Postgraduate Teaching Programme*, May 23, 1990; January 30 1991; May 22 1991

- Colorectal cancer, polyposis and bile. Surgical Meeting, *Central Middlesex Hospital*, London, June 1, 1990
- Bile, colorectal cancer and polyposis. Surgical Meeting, *St. Mary's Hospital*, London, June 11, 1990
- Colorectal cancer risk and uretero-sigmoidostomy. Combined Gastroenterology meeting, *St. Mary's Hospital*, London, June 15, 1990
- Evidence for the hamartoma-adenoma-carcinoma sequence. *St. Mark's Postgraduate Teaching Programme*, November 21, 1990
- The upper gastrointestinal tract in familial adenomatous polyposis. *FAP Teaching Day*, *St. Mark's Hospital*, London, November 22, 1990

1991

- Day care surgery – who, when and why? *General Practitioner Postgraduate Education Programme*, *Central Middlesex Hospital*, London, January 15, 1991
- Is breast screening a political gimmick? *Central Middlesex Hospital Medical Debating Society*, London, April 5, 1991
- Colorectal cancer research. Surgical Meeting, *Central Middlesex Hospital*, London, May 3, 1991
- Pharmacology and treatment in familial adenomatous polyposis. *Leeds Castle Polyposis Group* (Fourth Biennial Meeting), Fort Lauderdale, Florida, USA, May 9-11, 1991
- Surgical treatment of early breast cancer. *Central Middlesex Hospital Breast Cancer Study Day*, May 22, 1991
- What's new in colorectal cancer? *International College of Surgeons (Annual Meeting, British Section)* in Symposium on Multidisciplinary Aspects of Surgical Oncology, London, May 31, 1991
- Intestinal carcinogenesis and the environment. *Royal Postgraduate Medical School, Hammersmith Hospital* (Departments of Surgery & Gastroenterology), London, June 24, 1991
- Colorectal cancer: survival and surgery. *Institute of Cancer Research, Royal Marsden Hospital*, Sutton, Surrey, June 26, 1991

1992

- The genetics of colorectal cancer. *Royal Free Hospital*, London (Department of Surgery), July 15, 1992
- The upper gastrointestinal tract. *Thames Regions Registry FAP Teaching Day*, *St. Mark's Hospital*, London, October 10, 1992

1993

- Management of polyposis syndromes. *St. Mark's Hospital Lecture Course in Coloproctology*, October 16, 1992 & March 12, 1993
- Familial adenomatous polyposis – genetic alterations and implications for sporadic colorectal cancer. *Colorectal Cancer Teaching Day*, *Central Middlesex Hospital*, March 12, 1993
- Abnormal hepatic metabolism of carcinogens and colorectal carcinogenesis. *Colorectal Cancer Teaching Day*, *Central Middlesex Hospital*, March 12, 1993
- Problems of the duodenum in familial adenomatous polyposis. *Wessex Regional Clinical Genetics Service & the Association of Coloproctology (Wessex Chapter)*, Salisbury, April 16, 1993
- Polyposis syndromes. *British Postgraduate Medical Federation Advanced Course in Gastroenterology*, *St. Bartholomew's Hospital*, London, November 26, 1993
- Management of colorectal polyps. *Royal Society of Medicine (Section of Coloproctology)*, Coloproctology Teaching Day, Poole, December 10, 1993

1994

- Evidence for abnormal metabolism in FAP patients. *St. Mark's Hospital*, London (Grand Rounds), January 14, 1994
- New ideas in Familial Polyposis. Visit to *Northwick Park Hospital*, London, by Professor Zane Cohen, Toronto, (the Sir Alan Parks Visiting Professor to St. Mark's Hospital), June 20, 1994
- Conclusions from five years research into the pathogenesis of intestinal adenomas in FAP. *Combined Gastroenterology Meeting*, *Ichilov Hospital*, Tel Aviv, Israel, July 27 1994
- Chairman of Scientific Session on Gastrointestinal Cancer – Molecular Aspects. *British Society of Gastroenterology*, Edinburgh, September 22, 1994
- For Debate: that this house believes that everyone with FAP should have surgery as soon as possible. *Concerted Action Against Polyposis Meeting* (an EC initiative). Manchester October 22, 1994
- The Acute Abdomen. Teaching Session for *St. Mary's Hospital A & E Staff*. November 3, 1994
- The One-Stop Breast Clinic & the See & Treat Clinic. *St. Mary's Hospital GP Evening*, November 23, 1994
- Polyps and Polyposis Syndromes. *British Postgraduate Medical Federation Advanced Course in Gastroenterology*, *St. Mark's Hospital*, London, November 25, 1994

- New clinical and information initiatives at St. Mary's Hospital. *St. Mary's Hospital* GP Evening, December 1, 1994
- Polyposis Syndromes. *St. Mary's Hospital* Surgical Lecture, December 5, 1994

1995

- Symposium on Familial Adenomatous Polyposis: genotype-phenotype correlations. *Royal Society of Medicine*, Section of Coloproctology, January 25, 1995
- Management of polyposis syndromes. *St. Mark's Hospital Lecture Course in Coloproctology*, March 2, 1995
- Clinical Issues: Polyposis – Upper and Lower GI. *Coloproctology: State of the Art, Farewell to the City Road*. St. Mark's Hospital, June 21, 1995
- Neoplasia: Polyposis Syndromes. *St. Mark's Hospital Lecture Course in Coloproctology*, October 12, 1995
- Polyposis Syndromes. *British Postgraduate Medical Federation London Course in Gastroenterology*, St. Bartholomew's Hospital, November 13, 1995

1996

- Clinical Aspects of Breast Disease. MSc Course in Cytotology, *St. Mary's Hospital*, February 29, 1996
- Polyposis syndromes. *St. Mark's Hospital Lecture Course in Coloproctology*, March 1, 1996.
- Innovative Health Care Projects at St. Mary's. *GP Fundholding Conference*, Syon House, London, March 8, 1996
- All in a day's work. *St. Mary's District Medical Society*, London, March 12, 1996
- Breast Care in the Community. *Breast Care Symposium*. Dorchester Hotel London, June 10, 1996 (*Organiser and Speaker*)
- Hospital Information Technology Systems – the Surgeons Perspective. *Chelsea and Westminster Hospital Academic Surgical Unit Breakfast Meeting*, London, July 5, 1996
- Breast Disorders: Management of Benign Breast Disease and Surgical Management of Cancer. Multidisciplinary Symposium organised by *Samaritan Hospital for Women*, St. Mary's Hospital, London, September 20, 1996
- Polyposis Syndromes. *London Advanced Gastroenterology Course*, St. Mark's Hospital, November 11, 1996
- Polyposis Registries. *Edgware Postgraduate Medical Centre*, Middlesex, London. November 21, 1996

1997

- Running a familial bowel cancer clinic in London. *Fellows Meeting, Hunter Genetics*. Newcastle, Australia April 29, 1997
- Genesis of a Regional Family Cancer Registry. *St. Mark's Hospital In-House Rounds*, London, May 30, 1997
- Chairman of Chemoprevention Session, *7th Biennial Meeting, Leeds Castle Polyposis Group*, The Netherlands, June 7, 1997
- New initiatives in Family Cancer. *Tamworth Hospital Grand Rounds*, June 17, 1997.
- Genetics of Colorectal Cancer. *John Hunter Hospital Registrars' Training Meeting*, Newcastle, July 8, 1997
- Genetic Predisposition to Malignancies. *Royal Newcastle Hospital, Sexual Health Clinic Meeting*, Newcastle, July 8, 1997
- The Need for a Regional Family Cancer Registry. *Medical Grand Rounds, John Hunter Hospital*, Newcastle, July 17, 1997
- The Hunter Family Cancer Clinic. *Child and Youth Health Network, Department of Paediatric Endocrinology, John Hunter Hospital*, August 27, 1997
- A surgical pot-pourri. *Department of Anaesthetics and Intensive Care, John Hunter Hospital*, August 28, 1997
- Hereditary Bowel Cancer, *John Hunter Hospital, Department of Gastroenterology, Clinical Meeting*, August 28, 1997
- Surgery in the Newcastle Curriculum, *Country Term Supervisors' Meeting, The University of Newcastle* 12 September 1997
- The Hunter Family Cancer Clinic. *Paediatric Grand Rounds, John Hunter Hospital*, September 24, 1997
- Hereditary Gastrointestinal Cancer — the role of the Registry and Research. *Sydney Colorectal Society Journal Club*. September 29, 1997
- Surgical Teaching, *Gosford Hospital Education Centre*, October 23, 1997
- Management of Upper GI Lesions: *Annual Scientific Meeting of the Gastroenterological Society of Australia*. Brisbane, 29 October 1997
- Familial Cancer – Local Initiatives. *Medical Oncology Meeting, Mater Hospital*, November 5, 1997
- Quality Assurance. *Medical Oncology Quality Assurance Meeting, Mater Hospital*, November 6, 1997
- New Initiatives in the Hunter. *Hunter Surgical Society, Annual Weekend Meeting*; November 8, 1997
- You can no longer practise general surgery without a laparoscope. Debate at *Hunter Surgical Society, Annual*

Weekend Meeting, November 8, 1997

- A Surgical Quality Program. Meeting of the New South Wales State Committee of the *Royal Australian College of Medical Administrators*. Symposium on Management for Clinicians, Sydney, November 21, 1997
- Upper gastrointestinal disease. In FAP. From FAP Through Cancer Genetic Services. Meeting of the *Royal Society of Medicine*, London, 28 November 1997

1998

- Introduction to Computer Information System - Demonstration for Operating Theatres, *Hunter Area Health Service*, 23 February 1998
- Family Cancer Research Proposal. Presentation to the Chief Executive Officer of *Newcastle Permanent Building Society* and staff of *Hunter Family Cancer Service*, 24 February 1998, John Hunter Hospital
- The Effect of Modulation of Carcinogen Metabolising Enzymes on Biomarkers of Cancer Risk. *Hunter Medical Research*, John Hunter Hospital, 19 March 1998
- Family Adenomatous Polyposis and Hereditary Bowel Cancer, *South-West Colorectal Surgical Group*. Liverpool Hospital, New South Wales, 4 April 1998
- Familial Colorectal Cancer – Challenges and Solutions. *Sydney Gut Club*, Sydney Marriott Hotel, 6 May 1998
- Genetic Testing in Australia, *Royal Australasian College of Surgeons, Annual Scientific Meeting*, Sydney, 7 May 1998
- Genetic Testing in Australia. New Challenges. *Broken Hill Division of General Practice*, Broken Hill, 11 June 1998
- Genetic Testing in Australia 1998. *Broken Hill Community Health Centre*, Broken Hill, 11 June 1998
- Family Cancer – New Initiatives. Dubbo Hospital – Medical Grand Rounds, Dubbo 15 June 1998
- Familial Colorectal Cancer. *Combined Medical and Surgical Gastroenterology Meeting*. *Prince of Wales Hospital*, Sydney, New South Wales. Monday 20 July 1998
- Familial Bowel Cancer – New Initiatives. *Gosford Gut Club*, *Gosford Hospital*. 13 August 1998.
- How can we improve cardiac surgical services in the Hunter? *The Open Heart Association of Australia Inc.* John Hunter Hospital 14 October 1998
- Egyptian Mummy Project at Nicholson Museum, The University of Sydney. Launch of the Project Video Under Wraps: The Scientific Study of the Egyptian Mummies in the Nicholson Museum, *Nicholson Museum, University of Sydney*, Monday 19 October 1998
- Molecular Epidemiology Workshop – Newcastle Institute of Public Health. Presentation on 27 October 1998 entitled Genetic-environment interactions in inherited cancer. Chair session on 28 October
- Polyps, Cancers, Families; Genetics Tests now available. *Fourteenth Annual Scientific Meeting of Sydney Colorectal Surgical Society*, Sydney, 7 November 1998
- Genetic Testing for Familial Colorectal Cancer in Australia. *New South Wales Branch of the Human Genetics Society of Australasia*. Newcastle, 14 November 1998
- Family trees: From Now to the Valley of the Kings. *Newcastle Probus Club*, 24 November 1998

1999

- Colorectal Cancer: New developments. *Hunter Division of Urban General Practitioners*, Newcastle, 17 February 1999
- Hunter Family Cancer Service: *Medical Genetics in the Hunter: the Past Decade and the Next One*. Newcastle, 19 March 1999
- How to road-test your doctor and other health professionals – what they should be telling you about the service they provide. *Newcastle Institute of Public Health Seminar*, Newcastle, 23 March 1999
- Hunter Family Cancer Service. What Services are Available. *Cardiff Division of General Practice*. Newcastle, 7 April 1999
- Egyptology in New South Wales – The Curse of the Mummy. *Newcastle Business Club*. Newcastle, 20 April 1999
- Familial Colorectal Cancer. The role of family cancer clinics and Registers. *Central Coast Colorectal Cancer Working Group*. Gosford, 7 June 1999
- Familial Colorectal Cancer. *Surgical Meeting*, *Royal North Shore Hospital*, Sydney, 30 August 1999
- Clinical Governance. *Australian College of Health Service Executives*. John Hunter Hospital, Newcastle, 31 August 1999
- The role of Clinical Governance. *The Hunter Region Quality Management Forum*. Newcastle, 6 October 1999
- Colorectal Cancer Management – NH & MRC Guidelines and Audit. *Clinical Sciences Meeting*, *Canberra Hospital*, 24 November 1999

• Hereditary Bowel Cancer – Can we do better? *Gastroenterology Unit, Canberra Hospital*, 25 November 1999
2000

- Bowel Cancer Genetics. *Familial Cancer Clinic Meeting. Royal North Shore Hospital*, Sydney, 1 February 2000
- Clinical Governance: Veni, vidi, ? . *International Healthcare Risk Management Symposium*. Perth, 3-4 February 2000
- The Quality Council. *Hunter Area Health Service Business Planning Day*. Newcastle, 23 February 2000
- Patient Safety. *Improving the Dialogue between Management and Clinicians*. Hunter Area Health Service, Newcastle. 2 March 2000
- Patient safety – local initiatives. *Presentation to Chair of the National Council of Quality & Safety in Health Care*, Newcastle, 6 April 2000
- Clinical Indicators. *Hunter Area Health Service Business Planning Day*. Newcastle, 3 May 2000
- Day Surgery. *Mater Hospital Surgeons' Meeting*. 17 May 2000
- Clinical Governance and Patient Safety. *Strategic Action Group – Directors of Nursing, Hunter Area Health Service*, Newcastle, 18 May 2000
- Hereditary Colorectal Cancer. *Newcastle-Stockton Network of the Hunter Urban Division of General Practitioners*. Newcastle, 27 July 2000
- Familial Colorectal Cancer Management. *Graduate Diploma Course in Genetic Counselling*. Newcastle, 15 August 2000
- Clinical Governance - the first year. *Royal Newcastle Hospital Medical Staff Council*, 5 September 2000
- Clinical Risk Management. *2nd Scientific Meeting, General Surgeons Australia*, Sydney, 2 September 2000
- Overview and New Treatments in Hereditary Bowel Cancer. *NSW & ACT Hereditary Bowel Cancer Registers and Cancer Services Unit*, Paramatta, NSW, 4 November 2000

2001

- Clinical Governance. *Lower Hunter Sector Quality Council*, Maitland, 21 February, 2001
- Health Care Quality Indicators. *Hunter Area Health Service Business Planning Day*. Newcastle, 28 February, 2001
- Family Cancer: Cancer in the New Millenium. *Hunter Postgraduate Medical Institute*, Newcastle, 13 March, 2001
- Familial Colorectal Cancer. *Sydney Colorectal Surgical Society & the Hunter Surgical Society Meeting*, Hunter Valley, 23-25 March, 2001
- A Tale of Three Egyptian Mummies. *Nicholson Museum*, Sydney, 28 March, 2001
- Implementing Clinical Risk Management. *Australian Resource Centre for Hospital Innovations Meeting: 'Demystifying Clinical Governance'*, Canberra, 10 April, 2001
- Familial Colorectal Cancer. *Oncology Nurses of Australia*, Warners Bay, 23 May, 2001
- Highlights of the 2001 International Hereditary Bowel Cancer Meeting, Venice. *Family Cancer Clinics of NSW Meeting*, Sydney, 29 May, 2001
- Broccoli as an Anti-Carcinogen. *3rd 2001 Meeting of the Nutrition Society of Australia (Inc) – Newcastle group*, Newcastle, 25 July 2001
- Clinical Risk Management. *Hunter Surgical Society Meeting: "Risk Management and Law Reform"*, Newcastle, 10 August, 2001
- New Initiatives in Hunter Health. *Upper Hunter Sector Meeting*, Turanville via Scone, September 20, 2001
- Management of Familial Adenomatous Polyposis. *Christchurch Surgical Meeting – Colorectal Surgery*, Christchurch, New Zealand, October 18, 2001
- Colorectal Cancer Family Syndromes. *Christchurch Surgical Meeting – Colorectal Surgery*, Christchurch, New Zealand, October 18, 2001
- Colorectal Cancer Prevention "in the lab". *Christchurch Surgical Meeting – Colorectal Surgery*, Christchurch, New Zealand, October 18, 2001
- Clinical Quality Plan. *Hunter Area Health Service Business Planning Day*, Newcastle, October 31, 2001
- Clinical Governance. *Hunter Area Health Service Board Planning Day*, Pokolbin, December 6, 2001

2002

- Clinical Governance in the Hunter. *Clinical Risk Management Symposium, Northern Territory Department of Health & Community Services*, Darwin, March 15, 2002
- Implementing Clinical Governance. Opening Plenary Session, *Annual Scientific Congress, Royal Australasian College of Surgeons*, Adelaide, May 11, 2002

- Clinical Governance in Australia. *Australian Infection Control Association Second Biennial Conference*, Brisbane, June 7, 2002
- What has happened to surgical patients 30 days after discharge? *Hunter Area Health Service Business Planning Day*, Newcastle, July 31, 2002
- Hunter Family Cancer Service Update. *Newcastle Gut Club*, Newcastle, August 1, 2002
- The Long and Winding Road: Experience in patient safety initiatives since 1999 in a diverse Area Health Service. *Improving Patient Safety: Can we do more?* Australian Resource Centre for Hospital Innovations, Sydney, October 18, 2002
- Hunter Family Cancer Service Update. *Gosford Gut Club*, Gosford, October 31, 2002
- A Pilgrim's Progress: Patient Safety Initiatives under the Umbrella of Clinical Governance. *Patient Safety Launch, Princess Alexandra Hospital*, Brisbane, November 20, 2002

2003

- The NSW & ACT Hereditary Bowel Cancer Registers. *Cancer Genetics - Counselling Update*, Sydney, February 21, 2003
- Launch of Hunter Health's Clinical Risk Framework & Patient Safety Process. *Hunter Health Forum* - Newcastle, February 26, 2003
- Hereditary Bowel Cancer - An Overview. *NSW & ACT Hereditary Bowel Cancer Registers Information Day*, Sydney, March 5, 2003
- Diet and Cancer. *Cancer Information and Support Society, Hunter Branch*, Newcastle, March 19, 2003
- Hereditary Bowel Cancer Registers. *RACGP CPD Programme*, Tamworth, May 29, 2003
- Clinical Governance. *Lower Hunter Health Council*, Newcastle, September 29, 2003
- Clinical Governance. *Upper Hunter Health Council*, Muswellbrook, October 2, 2003
- Hunter Health Cancer Services & the NSW Cancer Framework. *Cancer Stakeholders*, Newcastle, October 15, 2003.
- The NSW Cancer Framework. *John Hunter Hospital Surgical CME Programme*, Newcastle, November 20, 2003
- Hereditary Cancer Registers. *NSW & ACT Hereditary Cancer Registers Public Information Day*, Newcastle, November 29, 2003
- Hospital Waiting Lists. Interview with Norman Swan, *The Health Report, ABC National Radio*, December 18, 2003. Transcript available at www.abc.net.au/rn/talks/8.30/healthrpt/stories/s1010746.htm

2004

- Patient Safety Systems. *Hunter Area Health Service Board*, February 10, 2004
- Launch of 'The Support and Information Pack & Cancer Answers'. *The Cancer Council NSW*, Newcastle, February 16, 2004
- Patient Safety Update. *Hunter Area Health Service Management Forum*, Newcastle, March 10, 2004
- Optimising Cancer Care. *Cancer Nurses Society of Australia*, Newcastle, March 24, 2004
- Clinical Governance in Hunter Health. *NSW Legislative Inquiry into Complaints Handling within NSW Health*, Sydney, March 29, 2004
- Clinical Governance - Measuring Performance. *CEO & Safety and Quality Leaders Forum*, Sydney, May 27, 2004
- Clinical Governance - Reporting from AIMS & Other Measures. *Director General's Safety Strategy Consultative Forum*, Sydney, June 1, 2004
- Professional Accountability. *Special Committee of Inquiry Forum*. Sydney, June 7-8, 2004
- Cancer in NSW - Pilots, Plans & Promises. *NSW Genetic Counsellors Workshop - Communicating in Family Cancer*, Sydney, June 17, 2004
- NSW and Hunter Plans for Cancer Services. *Hunter Postgraduate Medical Institute Seminar - Gynaecological Oncology*, Newcastle, June 26, 2004
- Case Study: Clinical Governance: Ensuring Best Practice Policy, Governance & Leadership in the Health Sector. *Lexis Nexis Health and Law Conference*, Sydney, July 1, 2004
- Cancer - Plans and Changes for Hunter New England Area Health Service. *Hunter Cancer Support Groups Meeting*, Newcastle, September 21, 2004
- Cancer Care in N.S.W. *Cancer Information & Support Society Inc.* Newcastle, October 20, 2004

2005

- Cancer Initiatives - Progress Report. *Hunter Gut Club*, Newcastle, April 7, 2005
- Implementing Clinical Governance. *Hong Kong Hospital Authority Convention*, Hong Kong, China, May 10,

2005

- How is medicine changing and how can we help each other? *Hunter Postgraduate Medical Institute*, Newcastle, July 26, 2005
- Cancer – the future in Hunter New England. *Cancer Council NSW Regional Forum*, Newcastle, August 5, 2005
- Clinical Governance. *Forster Review of Queensland Health*, Newcastle, August 9, 2005
- Clinical Governance in Hunter New England. *Senior Managers Orientation Day*, Newcastle, August 29, 2005
- Inherited Colorectal Cancer. *NSW & ACT Hereditary Cancer Registers - Information Evening on Hereditary Non Polyposis Colorectal Cancer syndrome (HNPCC)*. Sydney, November 23, 2005

2006

- Clinical Governance. *Northern Ireland Human Rights Commission*, Belfast, February 27, 2006
- Cancer Care Database Linkage. *Cancer Institute NSW*, Sydney, April 21, 2006
- Familial Pancreatic Cancer. *Upper GI Tumour Meeting*, St Vincents Hospital, Sydney, June 5, 2006
- Cancer Genetics. *John Hunter Hospital Surgeons CME Meeting*, June 22, 2006
- Hereditary Cancer. *Medical Grand Rounds, Gosford Hospital*, September 1, 2006
- Clinical Governance: What, Why & How. *2006 Dean's Lecture Series, University of NSW*, Sydney, October 18, 2006
- SV&MHS Cancer Plan – Progress. *Clinical Strategy Advisory Group*, St Vincent's Hospital, Sydney, November 2, 2006

2007

- Medicine and Social Justice. B'nai Brith Lecture Series, Sydney, April 29, 2007
- SV&MHS Cancer Plan. *St Vincents & Mater Health Service Board*, May 14, 2007
- Emerging technologies and techniques: Introduction into clinical practice. *Risk Management in Gynaecology and Endoscopic Surgery, XVII Annual Scientific Meeting of the Australian Gynaecological Endoscopy Society*, Sydney, May 17, 2007

2009

- Introduction to the Bussey Memorial Lecture, *International Society for Gastrointestinal Hereditary Tumours*, Dusseldorf, Germany, June 26, 2009
- Personalised Medicine, *Garvan Institute of Medical Research Public Lecture Series*, Sydney, August 25, 2009
- Garvan St Vincent's Campus Cancer Centre, *The Curran Foundation*, Sydney, October 1, 2009

2010

- Garvan St Vincent's Campus Cancer Centre, *Yale University School of Management*, Sydney, March 10, 2010
- What's new in Breast Cancer – Genetics. *Hunter Breast Cancer Pubic Forum 2010*. Newcastle, May 23, 2010
- Hereditary Cancer. *Taree Hospital Medical Grand Rounds*. May 27, 2010.
- Molecular Mechanisms in Colorectal Cancer: Session Chair. *Familial Cancer Conference*, Kingscliff, NSW, August 17, 2010

2011

- Panel member, Co-ordinators Corner. 4th Biennial meeting *International Society for Gastrointestinal Hereditary Tumours*, San Antonio, Texas, March 30, 2011
- Co-Chair, Plenary Session, Duodenal Polyposis and Desmoid Disease. 4th Biennial meeting *International Society for Gastrointestinal Hereditary Tumours*, San Antonio, Texas, April 1, 2011
- Cancer and the Chosen People: Why and What can we do? Maroubra Synagogue Lecture Series. May 11, 2011
- My son (daughter) the Doctor: Medical Schools in 2011. Maroubra Synagogue Lecture Series. May 17, 2011
- Cancer: Latest Research & Treatments. Garvan Institute of Medical Research Public Lecture Series. September 13, 2011
- Surgery and Risk. Shine Lawyers, Annual Meeting. Brisbane, November 18, 2011

2012

- Change Management and the Kinghorn Cancer Centre. SVMHS Human Resources Forum, May 10, 2012
- Address at the Official Opening of The Kinghorn Cancer Centre, Sydney, August 28, 2012
- Genomics – The new age of personalised medicine. Curran Foundation meeting, Sydney, September 5, 2012
- Australasian Jewish Medical Federation. Bowel Cancer and Genetics – where are we now? Sydney, October 28, 2012

2013

- International Translational Cancer Research Symposium. Translational Cancer Centres- The Kinghorn Cancer Centre. Sydney Catalyst. Sydney, May 6, 2013
- St Vincent's Patient Safety & Quality meeting. The Mid-Staffordshire Enquiry. May 28, 2013
- St Vincent's Clinic Board, Sydney. St Vincent's Campus Cancer Plan. June 11, 2013
- Inside St Vincent's 2013. The Curran Foundation – Breast Cancer. Sydney, July 30, 2013
- St Vincent's Cancer & Immunology Strategic Plan, St Vincent's Hospital Strategic Planning and Major Issues Committee, August 6, 2013
- International Society for Gastrointestinal Hereditary Tumours (InSiGHT) 5th Biennial Meeting, Meeting Convenor and Chair of multiple sessions, Cairns, Queensland, August 28-31, 2013
- St Vincent's Hospital Research Week Opening Address, Cancer Research, The Kinghorn Cancer Centre, Sydney September 3, 2013
- St Vincent's Hospital Medical Grand Rounds, Chair. Topics: Lynch Syndrome, Patrick Lynch & Sulindac and colon cancer mouse, Maija Kohonen-Corish. Sydney, September 3, 2013
- INSIGHT Program SBS television, recorded November 6, aired November 12. Topic: *A Time for Dying*

2014

- Realising Genomic Medicine in Australia. *Understanding Your Genome*. Garvan Institute Illumina meeting. April 8, 2014
- Radio Interview: Greek Community Radio, Sydney, April 27. *Cancer – Recent and Future Advances* Kaplan Medical Centre, *Cancer Genomics: Opportunity or Threat?* Rehovot, Israel, July 8, 2014
- St Vincent's Curran Foundation, *Inside St Vincent's 2014 – Hospital of the Future*. Sydney, August 26, 2014
- St Vincent's Campus Research Week, Open Day, *Familial Cancer – Predicting the Future*, Sydney, September 11, 2014
- National Council of Jewish Women, Sydney, Pink Sunday, *Breast Cancer Genetics and You*. October 26, 2014
- Hunter Breast Multidisciplinary meeting, Newcastle. *Genetic Issues Pertinent to Breast Cancer*. October 30, 2014
- Toormina Medical Practice, Coffs Harbour. *Breast Cancer Genetics*. November 5, 2014

2015

- International Society for GI Hereditary Tumours Biennial meeting, Sao Paolo, Brazil. *Upper GI disease in FAP – Introduction to Eldon Gardner Lecture*. Sao Paolo, Brazil, June 19, 2015
- Australian Lawyers Alliance Medical Law Conference. *Familial Cancer*. Sydney, 31 July, 2015
- PricewaterhouseCoopers Emerging Health Leaders Forum, Disruption in Healthcare. *Cancer Research & Care: Past, Present & Future*. Sydney, 27 August, 2015

2016

- Hunter New England Local Health District Cancer Clinical Network Leadership Committee Meeting. *Genetics: Family Cancer Services*. Newcastle, 18 March, 2016

2017

- St Vincent's Hospital Breast Cancer Support Group. *Breast cancer genetics – recent advances*. Sydney, January 31, 2017
- 2nd Australian Translational Breast Cancer Research Symposium. *Panel Member*, Garvan Institute, Sydney, February 14, 2017

- Professor Robin Phillips' Festschrift. *Polyposis Symposium, The upper GI tract*, The Royal College of Physicians, London, December 1, 2017

2018

- *Chair, RACS Keynote Lecture. Genomics, personalised medicine and what it means for the cancer surgeon.* Professor David Thomas. Sydney ASC RACS 9 May, 2018
- *Breast Cancer – Genetics.* Hunter Breast Cancer Education & Support Network, Body & Soul Forum, Newcastle, 29 July, 2018
- *Hereditary Gastrointestinal Cancer - 3 talks at 3 Hospitals (Vietnam).* Ha Long Bay Hospital, Hanoi Medical University Hospital, Bach Mai National Hospital, Vietnam, September 8 -13, 2018

2019

- *Cancer Genetics.* Staff seminar, Central Coast Cancer Centre, Gosford, June 21 2019
- *Cancer Screening.* Hoc Mai Advanced Course in Education and Research, Immersion Program, Royal North Shore Hospital, Sydney, June 27, 2019

Part 4: Committees (1997 -):**Education:**

Position	Committee	Group Represented	Year
Member	Academic Senate	University of Newcastle representing Faculty of Medicine and Health Sciences	1997 - 98
Chair	Conjoint Appointments Advisory Committee	University of Newcastle	1997 - 2004
Chair	Year 1, Block 2 Committee	University of Newcastle Bachelor of Medicine program (BMed)	1997 - 2000
Chair	Domain I (Professional Skills)	Faculty of Medicine and Health Sciences	1998 - 2000
Chair	Academic Responsibility Working Party	Faculty of Medicine and Health Sciences, The University of Newcastle	1997 - 98
Member	National Cancer Medical Education Committee Advisory Council	The University of Newcastle	1997 - 2002
Member	Year 1 Committee, (Surgical Representative)	University of Newcastle BMed Program	1997 - 1999
Member	Postgraduate Education	University of Newcastle	1997 - 1999
Member	Norwegian Medical Student Working Party	University of Newcastle BMed. Program	1997 - 1999
Member	Working Party - Library Service and Information	Faculty of Medicine and Health Sciences	1997 - 1998
Member	Oncology Strand Teaching	University of Newcastle BMed. program	1997 - 2002
Member	Health Informatics Courses Working Party	Faculty of Medicine and Health Sciences	1998 - 1999
Member	Space Committee	Faculty of Medicine and Health Sciences	1998 - 2000
Member	Information Technology Working Party, Faculty of Medicine & Health Sciences	Discipline of Surgical Science	1998 - 1999
Member	Hunter Postgraduate Medical Institute Board	Hunter Area Health Service	2001 - 2006
Member	St Vincent's Campus Education Committee	Surgery	2006 -
Member	Faculty of Medicine Board, UNSW Faculty Standing Committee, UNSW Higher Degree Committee	Surgery - St Vincent's Hospital Clinical School	2006 -

Member	Faculty of Medicine, UNSW – Curriculum Development Committee	St Vincent's Hospital Clinical School	2006 -
Member	Faculty of Medicine, UNSW – Independent Learning Project Committee	St Vincent's Hospital Clinical School	2006 -
Member	Faculty Executive Committee, UNSW	St Vincent's Hospital Clinical School	2007 -
Member	UNSW and St Vincents & Mater Health Sydney Liaison Committee	UNSW	2007 -

Health Service

Position	Committee	Group Represented	Year
Chair	Autopsy Committee	Hunter Area Health Service	1997 - 1998
Acting Chair	Division of Surgery	John Hunter Hospital	February - July 1998
Chair	John Hunter Hospital Division of Surgery	Hunter Area Health Service	July 1998 – May 1999
Chair	John Hunter Hospital Surgical Audit Unit	Hunter Area Health Service	1997 - 2001
Chair	Area Quality Use of Medicine Committee	Hunter Area Health Service	2001 - 2003
Chair	NSW Health Department New Interventional Procedures Committee	NSW Health / Hunter Area Health Service	2002
Member	Executive Management Committee	Division of Surgery John Hunter Hospital	1997 - 1999
Member	Pharmacy & Therapeutics Committee	Division of Surgery John Hunter Hospital	1997 - 1999
Member	Infection Control Committee	Division of Surgery John Hunter Hospital	1997 - 1999
Member	Clinical Pathways Steering Committee	Division of Surgery John Hunter Hospital	1997 - 1999
Member	Clinical Pathways Working Party	Division of Surgery John Hunter Hospital	1997 - 1999
Member	Clinical Pathways Interest Group	Division of Surgery John Hunter Hospital	1997 - 1999
Member	Day Surgery Policy Working Group, NSW Health	Hunter Area Health Service	1997 - 1999
Member	Postgraduate Medical Education & Training Steering Committee, Centre for Research & Clinical Policy, NSW Health	Hunter Area Health Service	1999 - 2001
Member	Centre for Mental Health Studies Management Committee, Hunter Health	CEO, Hunter Area Health Service	1999 - 2002
Member	Board of Newcastle Bone and Joint Institute	Discipline of Surgical Science, University of Newcastle; Hunter Area Health Service	1997 - 1999

Member	Quit Smoking for Surgery Project Advisory Group	Hunter Area Health Service	1998 - 2004
Member	Area Executive Team	Hunter Area Health Service	1999 - 2005
Member	Area Quality Council	Hunter Area Health Service	1999 - 2005
Member	Area Safety Leadership Council	Hunter Area Health Service	1999 - 2002
Member	Area Medical Appointments Advisory Committee	Hunter Area Health Service	1999 - 2005
Member	Health Services Planning and Performance Committee	Hunter Area Health Service	1999 - 2000
Member	Steering Committee: Patient Administration System (PAS) Implementation Project	Hunter Area Health Service	1999 - 2001
Member	Hunter Area Health Service Clinical Information Committee	Hunter Area Health Service	1999 - 2002
Member	Hunter Area Health Service Clinical Ethics Committee	Clinical Governance Unit	2000 - 2001
Member	Statewide Chronic and Complex Care Implementation Group	Hunter Area Health Service	2000 - 2001
Member	NSW Special Committee Investigating Deaths Associated with Surgery	Hunter Area Health Service / University of Newcastle	1999 - 2005
Member	Area Infection Control Executive and Committee	Hunter Area Health Service	2001 - 2006
Member	NSW Department of Health Retention of Body Parts at Post - Mortem	Hunter Area Health Service	2001 -2002
Member	NSW Department of Health Credentialling Working Group	Hunter Area Health Service	2002
Member	Perfecting Healthcare Delivery Project Steering Committee	Hunter Area Health Service	2002
Member	NSW Department of Health Clinical Governance Steering Group	Hunter Area Health Service	2002
Member	NSW Department of Health Cancer Genetics Working Party	Hunter Area Health Service	2003
Member	Steering Committee to Review Random Drug & Alcohol Testing of Medical Practitioners and other Relevant Health Professionals	Hunter Area Health Service	2003 - 2004
Member	NSW Department of Health Quality Improvement and Ethics Working Party	Hunter Area Health Service	2003
Member	Clinical Services Advisory Committee of the Cancer Institute N.S.W.	Hunter Area Health Service	2003 - 2005
Member	N.S.W. Medical Board	Universities of N.S.W.	2003 - 2008
Member	Governance Project Group	Hunter Health	2004
Member	Quality & Clinical Effectiveness Advisory Committee of the Cancer Institute N.S.W.		2003 - 2005
Member	N.S.W Cancer Genetics Oncology Group, Cancer Institute N.S.W.		2005 -

Member	N.S.W Colorectal Cancer Oncology Group, Cancer Institute N.S.W.		2005 - 2008
Member	Clinical Services Advisory Committee, Cancer Institute N.S.W.	SV&MHS	2005 - 2008
Member	St Vincent's Hospital Executive Management Committee	Cancer & Immunology Program	2006 -
Member	St.Vincent's Hospital Medical Staff Appointment and Credentials Advisory Committee (ex officio)		2006 -
Member	Campus Medical Council (ex officio): 2006 -		2006 -
Member	St Vincents Patient Safety & Quality Committee	Surgery	2006 -
Member	St Vincents & Mater Health Quality & Risk Management Committee (Board sub-committee); SV&MHS Executive Management Committee - Quality & Risk		2006 - 2010 2010-
Member	St Vincents Clinical Services Strategy Reference Group	Cancer Services	2006 - 2009
Member	Australian Safety & Efficacy Register of New Interventional Procedures – Surgical – Review Group re Guidelines and Policies for the Introduction of New Interventional Procedures		2007
Member	NSW Special Committee Investigating Deaths Associated with Surgery NSW Collaborating Hospitals' Audit of Surgical Mortality (CHASM)		2007 – 2008 2008 - 2018
Chair	NSW Health Live Donor Nephrectomy Review Working Party		2007
Member	NSW Quality Measure Reference Group – NSW Health		2007
Member	Australian Health Professions Regulatory Authority – Registration Committee		2012 -
Member	Agency for Clinical Innovation – Clinical Advisory Council	St Vincent's Hospital	2011 - 2012
Member	Aboriginal Cancer Partnership Project Advisory Committee, Cancer Institute NSW	St Vincent's Local Health Network	2012 - 2015
Member	Cancer Institute NSW Quality and Clinical Effectiveness Advisory Committee	Directors of Cancer Services – Local Health Districts	2013 - 2015
Member	St Vincent's Hospital Antimicrobial Stewardship Committee		2014 -
Member	St Vincent's Health Network Radiation Oncology Steering Committee		2014 - 2015
Member	Antimicrobial Stewardship Expert Advisory Committee – NSW Clinical Excellence Commission	Surgical Representative	2015 -

Member	N.S.W. Medical Board		2015 -
--------	----------------------	--	--------

Health Service and Research

Position	Committee	Group Represented	Year
Chairman	Advisory Committee, NSW & ACT Hereditary Cancer Register		1997 - 2006
Member	Australian Cancer Network Genetics Working	Hunter Area Health Service	1997 - 1998
Member	Colorectal Cancer Screening Working Party Sub-Committee Australian Cancer Network	Hunter Area Health Service; University of Newcastle	1997- 1998
Member	National Hospital Demonstration Project (NHDP) Phase II Committee	Division of Surgery John Hunter Hospital	1997 – 1999
Member	NDHP Clearing House Committee	Division of Surgery, John Hunter Hospital. Surgical Science, University of Newcastle	1997 – 1999
Member	Local Management Committee, Australian Resource Centre for Hospital Innovations (NDHP Clearing House)	Division of Surgery, John Hunter Hospital	1998 - 1999
Member	Organising Committee, 2nd Joint Meeting of the International Collaborative Group, Hereditary Non-Polyposis Colorectal Cancer and the Leeds Castle Polyposis Group, Melbourne, March 1999	Hunter Family Cancer Service	1997 – 1999
Member	Hunter Medical Research Council	Hunter Family Cancer Service	1998 - 2000
Member	Steering Committee, <i>Hospital in the Home Project</i> , Department of Health and Family Services, Commonwealth of Australia	Hunter Area Health Service	1998 - 1999
Member	Cancer Genetics Working Party, New South Wales Genetics Service, Department of Health	Hunter Family Cancer Service	1998 - 1999
Chair	Clinical Governance Reference Group	Clinical Governance Unit, Hunter Area Health Service	2000 - 2002
Member	Steering Committee for Day Surgery Consultancy, Department of Health and Family Services, Commonwealth Department of Health	Hunter Area Health Service	1998 - 1999
Member	National Cancer Control Initiative, Familial Cancer Working Party	Hunter Area Health Service	1999 - 2000
Member	Council of the Leeds Castle Polyposis Group (International Committee)	NSW & ACT Hereditary Bowel Cancer Registers	1999 - 2003
Member	Colorectal Cancer Working Party	NSW Cancer Council	1999 - 2000
Member	Heart and Stroke Health Outcomes Council	Hunter Area Health Service	1999 - 2001

Member	Executive, Newcastle Institute of Public Health	The University of Newcastle	1999 - 2000
Member	Steering Committee, Towards a Safer Culture Project	Hunter Area Health Service	2000 - 2002
Member	Model of Supportive Care Advisory Group, NSW Cancer Council	Hunter Area Health Service	2000 - 2002
Member Depouty Chair Chair	Governing Council, International Society for GI Hereditary Tumours (InSight)		2005 – Deputy Chair, 2009– 2011 Chair, 2013-2015
Member	NSW Acute Postoperative Pain Project: Reference Committee	St Vincents Hospital	2006 -2007
Member	St Vincent's Hospital Tissue Bank Committee	Cancer Program	2006 -2010
Member	Project Control Group, Kinghorn Cancer Centre	St Vincent's Hospital	2007 - 2012
Member	Project Working Group, Kinghorn Cancer Centre	St Vincent's Hospital	2007 - 2012
Member	International Cancer Benchmarking Partnership (ICBP) – leading to Lancet paper 2011		2010 - 2011
Member	Sr Vincent's Translational Research Project Steering Committee	Cancer Services & UNSW St Vincent's Clinical School	2011 - 2013
Member	NSW Cancer Survivors Centre Executive Committee	Cancer Services & UNSW St Vincent's Clinical School	2011 - 2014
Member	Sydney Catalyst Translational Cancer Research Governing Council	The Kinghorn Cancer Centre	2013 - 2015
Member	Sydney Catalyst Translational Cancer Research Advisory Committee	The Kinghorn Cancer Centre	2013 - 2015
Chair	Executive Management Committee, The Kinghorn Cancer Centre		2013 - 2015
Member	Primary Prevention subcommittee for NHMRC Guidelines – Colorectal Cancer		2015-2016
Clinical Lead (Lower GI) & Member	International Cancer Benchmarking Partnership (ICBP)		2016 -

Research:

Position	Committee	Group Represented	Year
Member	Clinical Advisory Committee New South Wales Cancer Council Colorectal Cancer Project	University of Newcastle	1997 - 1998

Member	Molecular Biology Working Group	Hunter Area Pathology Service	1997 -1998
Member	Hunter Institute of Medical Research Working Party	Discipline of Surgical Science, University of Newcastle	1997 – 1998
Chair	National Colorectal Cancer Care Survey	Hunter Area Health Service; University of Newcastle	2000 - 2002
Member	Colorectal Cancer Services Research Group	St. Vincent's Hospital	2005 - 2006
Member	Expert Review Panel, UNSW Faculty of Medicine		2010
Member	St Vincent's Health Network Research Council		2014 -

Information Management and Technology:

Position	Committee	Group Represented	Year
Member	Information Systems Steering Committee - John Hunter Hospital	Division of Surgery John Hunter Hospital	1997 - 1999
Member	Clinical Information Committee Hunter Area Health Service	Division of Surgery John Hunter Hospital	1997 - 1999
Member	Operating Theatre System Project Working Party New South Wales Department of Health	Discipline of Surgical Science, University of Newcastle Division of Surgery John Hunter Hospital	1997 - 1998
Member	Clinical Systems Reference Group, New South Wales Department of Health	Discipline of Surgical Science, University of Newcastle Division of Surgery John Hunter Hospital	1997 - 1999
Member	Health Informatics Working Group Faculty of Medicine and Health Sciences, The University of Newcastle	Discipline of Surgical Science, University of Newcastle	1997 - 1998
Member	Steering Group, Hunter Urban Division of General Practice Project: Development of a Computer-generated Electronic Discharge Summary	Division of Surgery John Hunter Hospital	1997 - 1998
Member	Clinical Informatics Representative, Department of Health NSW	Hunter Area Health Service	1997 - 1999
Member	Hunter Area Telemedicine Trials Steering Committee	Division of Surgery, John Hunter Hospital	1998 - 1999
Member	Hunter Area Information Systems Steering Committee	Division of Surgery, John Hunter Hospital	1998 - 1999
Chair	Point of Care Clinical Systems Steering Committee	Hunter Area Health Service	2000 - 2001
Member	St Vincent's Hospital MOSAIQ Steering Committee		2014 - 2015